Hubbry Logo
search
logo
Yellow fever avatar
Yellow fever
Yellow fever
current hub
2315536

Yellow fever

logo
Community Hub0 Subscribers
Read side by side
Yellow fever
View on Wikipedia
from Wikipedia

Yellow fever
Other namesYellow jack, yellow plague,[1] bronze john[2]
A TEM micrograph of Yellow fever virus (234,000× magnification)
SpecialtyInfectious disease
SymptomsFever, chills, muscle pain, headache, Nausea, Vomiting, Fatigue, loss of appetite, yellow skin[3]
ComplicationsLiver failure, bleeding[3]
Usual onset3–6 days post exposure[3]
Duration3–4 days[3]
CausesYellow fever virus spread by mosquitoes[3]
Diagnostic methodBlood test[4]
PreventionYellow fever vaccine[3]
TreatmentSupportive care[3]
Frequency≈130,000 severe cases in Africa alone (2013)[3][5]
Deaths≈78,000 in Africa alone (2013)[3][5]

Yellow fever is a viral disease of typically short duration.[3] In most cases, symptoms include fever, chills, loss of appetite, nausea, muscle pains—particularly in the back—and headaches.[3] Symptoms typically improve within five days.[3] In about 15% of people, within a day of improving the fever recurs, abdominal pain occurs and liver damage begins, causing yellow skin.[3][6] If this occurs, the risk of bleeding and kidney problems is increased.[3][7]

The disease is caused by the yellow fever virus and is spread by the bite of an infected mosquito.[3][8] It infects humans, other primates,[9] and several types of mosquitoes.[3] In cities, it is spread primarily by Aedes aegypti, a type of mosquito found throughout the tropics and subtropics.[3] The virus is an RNA virus of the genus Orthoflavivirus, with a full scientific name Orthoflavivirus flavi.[10] The disease may be difficult to tell apart from other illnesses, especially in the early stages.[3] To confirm a suspected case, blood-sample testing with a polymerase chain reaction is required.[4]

A safe and effective vaccine against yellow fever exists, and some countries require vaccinations for travelers.[3] Other efforts to prevent infection include reducing the population of the transmitting mosquitoes.[3] In areas where yellow fever is common, early diagnosis of cases and immunization of large parts of the population are important to prevent outbreaks.[3] Once a person is infected, management is symptomatic; no specific measures are effective against the virus.[3] Death occurs in up to half of those who get severe disease.[3][11]

In 2013, yellow fever was estimated to have caused 130,000 severe infections and 78,000 deaths in Africa.[3][5] Approximately 90 percent of an estimated 200,000 cases of yellow fever per year occur in Africa.[12] Nearly a billion people live in an area of the world where the disease is common.[3] It is common in tropical areas of the continents of South America and Africa,[13] but not in Asia.[3][14] Since the 1980s, the number of cases of yellow fever has been increasing.[3][15] This is believed to be due to fewer people being immune, more people living in cities, people moving frequently, and changing climate increasing the habitat for mosquitoes.[3]

The disease originated in Africa and spread to the Americas starting in the 17th century with the European trafficking of enslaved Africans from sub-Saharan Africa.[1][16] Since the 17th century, several major outbreaks of the disease have occurred in the Americas, Africa, and Europe.[1] In the 18th and 19th centuries, yellow fever was considered one of the most dangerous infectious diseases; numerous epidemics swept through major cities of the US and in other parts of the world.[1]

In 1927, the yellow fever virus became the first human virus to be isolated.[17][18]

Signs and symptoms

[edit]

Yellow fever begins after an incubation period of three to six days.[19] Most cases cause only mild infection with fever, headache, chills, back pain, fatigue, loss of appetite, muscle pain, nausea, and vomiting.[20] In these cases, the infection lasts only three to six days.[21]

In 15% of cases, the disease enters a second, toxic phase, characterized by recurring fever, accompanied by jaundice caused by liver damage, as well as abdominal pain.[22] Bleeding in the mouth, nose, eyes and gastrointestinal tract causes vomit containing blood, hence one of the names in Spanish for yellow fever, vómito negro ("black vomit").[23] There may also be kidney failure, hiccups, and delirium.[24][25]

Among those who develop jaundice, the fatality rate is 20 to 50%, while the overall fatality rate is about 3 to 7.5%.[26] Severe cases may have a mortality rate greater than 50%.[27]

Surviving the infection provides lifelong immunity,[28] generally with no permanent organ damage.[29][30]

Complication

[edit]

Yellow fever can lead to death for 20% to 50% of those who develop severe disease. Jaundice, fatigue, heart rhythm problems, seizures and internal bleeding may also appear as complications of yellow fever during recovery time.[8][31]

Cause

[edit]
Yellow fever virus
Flavivirus structure and genome
Virus classification Edit this classification
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Kitrinoviricota
Class: Flasuviricetes
Order: Amarillovirales
Family: Flaviviridae
Genus: Orthoflavivirus
Species:
Orthoflavivirus flavi

Yellow fever is caused by Yellow fever virus (YFV), an enveloped RNA virus 40–50 nm in width, the type species and namesake of the family Flaviviridae.[17] It was the first illness shown to be transmissible by filtered human serum and transmitted by mosquitoes, by American doctor Walter Reed around 1900.[32] The positive-sense, single-stranded RNA is around 10,862 nucleotides long and has a single open reading frame encoding a polyprotein.[33] Host proteases cut this polyprotein into three structural (C, prM, E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5); the enumeration corresponds to the arrangement of the protein coding genes in the genome.[34] Minimal YFV 3′UTR region is required for stalling of the host 5′-3′ exonuclease XRN1.[35] The UTR contains PKS3 pseudoknot structure, which serves as a molecular signal to stall the exonuclease and is the only viral requirement for subgenomic flavivirus RNA (sfRNA) production.[36] The sfRNAs are a result of incomplete degradation of the viral genome by the exonuclease and are important for viral pathogenicity.[37] Yellow fever belongs to the group of hemorrhagic fevers.[38]

The viruses infect, amongst others, monocytes, macrophages, Schwann cells, and dendritic cells. They attach to the cell surfaces via specific receptors and are taken up by an endosomal vesicle.[39] Inside the endosome, the decreased pH induces the fusion of the endosomal membrane with the virus envelope.[40] The capsid enters the cytosol, decays, and releases the genome.[41] Receptor binding, as well as membrane fusion, are catalyzed by the protein E, which changes its conformation at low pH, causing a rearrangement of the 90 homodimers to 60 homotrimers.[34][42]

After entering the host cell, the viral genome is replicated in the rough endoplasmic reticulum (ER) and in the so-called vesicle packets.[43] At first, an immature form of the virus particle is produced inside the ER, whose M-protein is not yet cleaved to its mature form, so is denoted as precursor M (prM) and forms a complex with protein E.[44] The immature particles are processed in the Golgi apparatus by the host protein furin, which cleaves prM to M.[45] This releases E from the complex, which can now take its place in the mature, infectious virion.[34]

Transmission

[edit]
Aedes aegypti feeding
Adults of the yellow fever mosquito A. aegypti: The male is on the left, females are on the right. Only the female mosquito bites humans to transmit the disease.

Yellow fever virus is mainly transmitted through the bite of the yellow fever mosquito Aedes aegypti, but other mostly Aedes mosquitoes such as the tiger mosquito (Aedes albopictus) can also serve as a vector for this virus.[46] Like other arboviruses, which are transmitted by mosquitoes, Yellow fever virus is taken up by a female mosquito when it ingests the blood of an infected human or another primate.[47] Viruses reach the stomach of the mosquito, and if the virus concentration is high enough, the virions can infect epithelial cells and replicate there. From there, they reach the haemocoel (the blood system of mosquitoes) and from there the salivary glands.[48] When the mosquito next sucks blood, it injects its saliva into the wound, and the virus reaches the bloodstream of the bitten person.[49] Transovarial transmissionial and transstadial transmission of yellow fever virus within A. aegypti, that is, the transmission from a female mosquito to its eggs and then larvae, are indicated.[50] This infection of vectors without a previous blood meal seems to play a role in single, sudden breakouts of the disease.[51]

Three epidemiologically different infectious cycles occur[15] in which the virus is transmitted from mosquitoes to humans or other primates.[52] In the "urban cycle", only the yellow fever mosquito A. aegypti is involved. It is well adapted to urban areas, and can also transmit other diseases, including Zika fever, dengue fever, and chikungunya.[53] The urban cycle is responsible for the major outbreaks of yellow fever that occur in Africa. Except for an outbreak in Bolivia in 1999, this urban cycle no longer exists in South America.[54]

Besides the urban cycle, both in Africa and South America, a sylvatic cycle (forest or jungle cycle) is present, where Aedes africanus (in Africa) or mosquitoes of the genus Haemagogus and Sabethes (in South America) serve as vectors.[55] In the jungle, the mosquitoes infect mainly nonhuman primates; the disease is mostly asymptomatic in African primates.[49] In South America, the sylvatic cycle is currently the only way unvaccinated humans can become infected, which explains the low incidence of yellow fever cases on the continent.[46] People who become infected in the jungle can carry the virus to urban areas, where A. aegypti acts as a vector. Because of this sylvatic cycle, yellow fever cannot be eradicated except by completely eradicating the mosquitoes that serve as vectors.[15]

In Africa, a third infectious cycle known as "savannah cycle" or intermediate cycle, occurs between the jungle and urban cycles.[56] Different mosquitoes of the genus Aedes are involved. In recent years, this has been the most common form of transmission of yellow fever in Africa.[57]

Concern exists about yellow fever spreading to southeast Asia, where its vector A. aegypti already occurs.[58]

Pathogenesis

[edit]

After transmission from a mosquito, the viruses replicate in the lymph nodes and infect dendritic cells in particular. From there, they reach the liver and infect hepatocytes (probably indirectly via Kupffer cells), which leads to eosinophilic degradation of these cells and to the release of cytokines. Apoptotic masses known as Councilman bodies appear in the cytoplasm of hepatocytes.[59][60]

Fatality may occur when cytokine storm, shock, and multiple organ failure follow.[26]

Diagnosis

[edit]

Yellow fever is most frequently a clinical diagnosis, based on symptomatology and travel history. Mild cases of the disease can only be confirmed virologically.[47] Since mild cases of yellow fever can also contribute significantly to regional outbreaks, every suspected case of yellow fever (involving symptoms of fever, pain, nausea, and vomiting 6–10 days after leaving the affected area) is treated seriously.[47]

If yellow fever is suspected, the virus cannot be confirmed until 6–10 days following the illness. A direct confirmation can be obtained by reverse transcription polymerase chain reaction, where the genome of the virus is amplified.[4] Another direct approach is the isolation of the virus and its growth in cell culture using blood plasma; this can take 1–4 weeks.[61][12]

Serologically, an enzyme-linked immunosorbent assay during the acute phase of the disease using specific IgM against yellow fever or an increase in specific IgG titer (compared to an earlier sample) can confirm yellow fever.[62] Together with clinical symptoms, the detection of IgM or a four-fold increase in IgG titer is considered sufficient indication for yellow fever. As these tests can cross-react with other flaviviruses, such as dengue virus, these indirect methods cannot conclusively prove yellow fever infection.[63]

Liver biopsy can verify inflammation and necrosis of hepatocytes and detect viral antigens. Because of the bleeding tendency of yellow fever patients, a biopsy is only advisable post mortem to confirm the cause of death.[64]

In a differential diagnosis, infections with yellow fever must be distinguished from other feverish illnesses such as malaria. Other viral hemorrhagic fevers, such as Ebola virus, Lassa virus, Marburg virus, and Junin virus, must be excluded as the cause.[65]

Prevention

[edit]

Personal prevention of yellow fever includes vaccination and avoidance of mosquito bites in areas where yellow fever is endemic.[46] Institutional measures for the prevention of yellow fever include vaccination programmes and measures to control mosquitoes. Programmes for distribution of mosquito nets for use in homes produce reductions in malaria and yellow fever. EPA-registered insect repellent is recommended when outdoors. Exposure for even a short time is enough for a potential mosquito bite. Long-sleeved clothing, long pants, and socks are useful for prevention. Applying larvicides to water-storage containers can help eliminate potential mosquito breeding sites. EPA-registered insecticide spray decreases the transmission of yellow fever.[66]

  • Use insect repellent when outdoors such as those containing DEET, picaridin, ethyl butylacetylaminopropionate (IR3535), or oil of lemon eucalyptus on exposed skin.[67]
  • Mosquitoes may bite through thin clothing, so spraying clothes with repellent containing permethrin or another EPA-registered repellent gives extra protection.[68] Clothing treated with permethrin is commercially available. Mosquito repellents containing permethrin are not approved for application directly to the skin.[69]
  • The peak biting times for many mosquito species are dusk to dawn. However, A. aegypti, one of the mosquitoes that transmit yellow fever virus, feeds during the daytime.[70] Staying in accommodations with screened or air-conditioned rooms, particularly during peak biting times, also reduces the risk of mosquito bites.[70]

Vaccination

[edit]
Main article: Yellow fever vaccine
The cover of a certificate that confirms the holder has been vaccinated against yellow fever
Vaccination against yellow fever 10 days before entering this country/territory is required for travellers coming from...[71]
  All countries
  Risk countries (including airport transfers)[note 1]
  Risk countries (excluding airport transfers)[note 2]
  No requirement (risk country)[note 3]
  No requirement (non-risk country)

Vaccination is recommended for those traveling to affected areas, because non-native people tend to develop more severe illness when infected. Protection begins by the 10th day after vaccine administration in 95% of people,[72] and had been reported to last for at least 10 years. The World Health Organization (WHO) now states that a single dose of vaccine is sufficient to confer lifelong immunity against yellow fever disease.[73] The attenuated live vaccine stem 17D was developed in 1937 by Max Theiler.[72] The WHO recommends routine vaccination for people living in affected areas between the 9th and 12th month after birth.[4]

Up to one in four people experience fever, aches, local soreness, and redness at the injection site.[74] In rare cases (less than one in 200,000 to 300,000),[72] the vaccination can cause yellow fever vaccine-associated viscerotropic disease, which is fatal in 60% of cases. It is probably due to the genetic morphology of the immune system. Another possible side effect is an infection of the nervous system, which occurs in one in 200,000 to 300,000 cases, causing yellow fever vaccine-associated neurotropic disease, which can lead to meningoencephalitis and is fatal in less than 5%[72] of cases.[4][26]

The Yellow Fever Initiative, launched by the WHO in 2006, vaccinated more than 105 million people in 14 countries in West Africa.[75] No outbreaks were reported during 2015. The campaign was supported by the GAVI alliance and governmental organizations in Europe and Africa.[76] According to the WHO, mass vaccination cannot eliminate yellow fever because of the vast number of infected mosquitoes in urban areas of the target countries, but it will significantly reduce the number of people infected.[77]

Demand for yellow fever vaccines has continued to increase due to the growing number of countries implementing yellow fever vaccination as part of their routine immunization programmes.[78] Recent upsurges in yellow fever outbreaks in Angola (2015), the Democratic Republic of Congo (2016), Uganda (2016), and more recently in Nigeria and Brazil in 2017 have further increased demand, while straining global vaccine supply.[78][79] Therefore, to vaccinate susceptible populations in preventive mass immunization campaigns during outbreaks, fractional dosing of the vaccine is being considered as a dose-sparing strategy to maximize limited vaccine supplies.[78] Fractional dose yellow fever vaccination refers to administration of a reduced volume of vaccine dose, which has been reconstituted as per manufacturer recommendations.[78][80] The first practical use of fractional dose yellow fever vaccination was in response to a large yellow fever outbreak in the Democratic Republic of the Congo in mid-2016.[78] Available evidence shows that fractional dose yellow fever vaccination induces a level of immune response similar to that of the standard full dose.[81]

In March 2017, the WHO launched a vaccination campaign in Brazil with 3.5 million doses from an emergency stockpile.[82] In March 2017 the WHO recommended vaccination for travellers to certain parts of Brazil.[83] In March 2018, Brazil shifted its policy and announced it planned to vaccinate all 77.5 million currently unvaccinated citizens by April 2019.[84]

Compulsory vaccination

[edit]

Some countries in Asia are considered to be potentially in danger of yellow fever epidemics, as both mosquitoes with the capability to transmit yellow fever as well as susceptible monkeys are present.[85] The disease does not yet occur in Asia. To prevent the introduction of the virus, some countries demand previous vaccination of foreign visitors who have passed through yellow fever areas.[86] Vaccination has to be proved by a vaccination certificate, which is valid 10 days after the vaccination and lasts for 10 years. Although the WHO on 17 May 2013 advised that subsequent booster vaccinations are unnecessary, an older (than 10 years) certificate may not be acceptable at all border posts in all affected countries. A list of the countries that require yellow fever vaccination is published by the WHO.[71] If the vaccination cannot be given for some reason, dispensation may be possible. In this case, an exemption certificate issued by a WHO-approved vaccination center is required. Although 32 of 44 countries where yellow fever occurs endemically do have vaccination programmes, in many of these countries, less than 50% of their population is vaccinated.[4]

Vector control

[edit]
Information campaign for prevention of dengue and yellow fever in Paraguay

Control of the yellow fever mosquito A. aegypti is of major importance, especially because the same mosquito can also transmit dengue fever and chikungunya disease.[87] A. aegypti breeds preferentially in water, for example, in installations by inhabitants of areas with precarious drinking water supplies, or in domestic refuse, especially tires, cans, and plastic bottles. These conditions are common in urban areas in developing countries.[88]

Two main strategies are employed to reduce A. aegypti populations.[89] One approach is to kill the developing larvae. Measures are taken to reduce the water accumulations in which the larvae develop. Larvicides are used, along with larvae-eating fish and copepods, which reduce the number of larvae.[90] For many years, copepods of the genus Mesocyclops have been used in Vietnam for preventing dengue fever.[91] This eradicated the mosquito vector in several areas. Similar efforts may prove effective against yellow fever. Pyriproxyfen is recommended as a chemical larvicide, mainly because it is safe for humans and effective in small doses.[4]

The second strategy is to reduce populations of the adult yellow fever mosquito. Lethal ovitraps can reduce Aedes populations, using lesser amounts of pesticide because it targets the pest directly.[92] Curtains and lids of water tanks can be sprayed with insecticides, but application inside houses is not recommended by the WHO.[93] Insecticide-treated mosquito nets are effective, just as they are against the Anopheles mosquito that carries malaria.[4]

Treatment

[edit]

As with other Flavivirus infections, no cure is known for yellow fever. Hospitalization is advisable and intensive care may be necessary because of rapid deterioration in some cases. Certain acute treatment methods lack efficacy: passive immunization after the emergence of symptoms is probably without effect; ribavirin and other antiviral drugs, as well as treatment with interferons, are ineffective in yellow fever patients.[26] Symptomatic treatment includes rehydration and pain relief with drugs such as paracetamol (acetaminophen). However, aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are often avoided because of an increased risk of gastrointestinal bleeding due to their anticoagulant effects.[94]

Epidemiology

[edit]

Yellow fever is common in tropical and subtropical areas of South America and Africa.[95] Worldwide, about 600 million people live in endemic areas. The WHO estimates 200,000 cases of yellow fever worldwide each year.[96] About 15% of people infected with yellow fever progress to a severe form of the illness, and up to half of those will die, as there is no cure for yellow fever.[97]

Africa

[edit]
Areas with risk of yellow fever in Africa (2017)

An estimated 90% of yellow fever infections occur on the African continent.[4] In 2016, a large outbreak originated in Angola and spread to neighboring countries before being contained by a massive vaccination campaign.[98] In March and April 2016, 11 imported cases of the Angola genotype in unvaccinated Chinese nationals were reported in China, the first appearance of the disease in Asia in recorded history.[99][100]

Phylogenetic analysis has identified seven genotypes of yellow fever viruses, and they are assumed to be differently adapted to humans and to the vector A. aegypti. Five genotypes (Angola, Central/East Africa, East Africa, West Africa I, and West Africa II) occur only in Africa. West Africa genotype I is found in Nigeria and the surrounding region.[101] West Africa genotype I appears to be especially infectious, as it is often associated with major outbreaks. The three genotypes found outside of Nigeria and Angola occur in areas where outbreaks are rare. Two outbreaks, in Kenya (1992–1993) and Sudan (2003 and 2005), involved the East African genotype, which had remained undetected in the previous 40 years.[102]

South America

[edit]
Areas with risk of yellow fever in South America (2018)

In South America, two genotypes have been identified (South American genotypes I and II).[15] Based on phylogenetic analysis these two genotypes appear to have originated in West Africa[103] and were first introduced into Brazil.[104] The date of introduction of the predecessor African genotype which gave rise to the South American genotypes appears to be 1822 (95% confidence interval 1701 to 1911).[104] The historical record shows an outbreak of yellow fever occurred in Recife, Brazil, between 1685 and 1690. The disease seems to have disappeared, with the next outbreak occurring in 1849.[105] It was likely introduced with the trafficking of slaves through the slave trade from Africa. Genotype I has been divided into five subclades, A through E.[106]

In late 2016, a large outbreak began in Minas Gerais state of Brazil that was characterized as a sylvatic or jungle epizootic.[107] Real-time phylogenetic investigations at the epicentre of the outbreak revealed that the outbreak was caused by the introduction of a virus lineage from the Amazon region into the southeast region around July 2016,[108] spreading rapidly across several neotropical monkey species, including brown howler monkeys,[109] which serve as a sentinel species for yellow fever. No cases had been transmitted between humans by the A. aegypti mosquito, which can sustain urban outbreaks that can spread rapidly. In April 2017, the sylvatic outbreak continued moving toward the Brazilian coast, where most people were unvaccinated.[83] By the end of May the outbreak appeared to be declining after more than 3,000 suspected cases, 758 confirmed and 264 deaths confirmed to be yellow fever.[110] The Health Ministry launched a vaccination campaign and was concerned about spread during the Carnival season in February and March. The CDC issued a Level 2 alert (practice enhanced precautions.)[111]

A Bayesian analysis of genotypes I and II has shown that genotype I accounts for virtually all the current infections in Brazil, Colombia, Venezuela, and Trinidad and Tobago, while genotype II accounted for all cases in Peru.[112] Genotype I originated in the northern Brazilian region around 1908 (95% highest posterior density interval [HPD]: 1870–1936). Genotype II originated in Peru in 1920 (95% HPD: 1867–1958).[112] The estimated rate of mutation for both genotypes was about 5 × 10−4 substitutions/site/year, similar to that of other RNA viruses.[112]

Asia

[edit]

The main vector (A. aegypti) also occurs in tropical and subtropical regions of Asia, the Pacific, and Australia, but yellow fever had never occurred there until jet travel introduced 11 cases from the 2016 Angola and DR Congo yellow fever outbreak in Africa. Proposed explanations include:[113]

  • That the strains of the mosquito in the east are less able to transmit Yellow fever virus.[citation needed]
  • That immunity is present in the populations because of other diseases caused by related viruses (for example, dengue).[114]
  • That the disease was never introduced because the shipping trade was insufficient.

But none is considered satisfactory.[115][116] Another proposal is the absence of a slave trade to Asia on the scale of that to the Americas.[117] The trans-Atlantic slave trade probably introduced yellow fever into the Western Hemisphere from Africa.[118]

History

[edit]
Main article: History of yellow fever

Early history

[edit]
Sugar curing house, 1762: Sugar pots and jars on sugar plantations served as breeding place for larvae of A. aegypti, the vector of yellow fever.
Headstones of people who died in the yellow fever epidemic of 1878 can be found in New Orleans' cemeteries
A page from Commodore James Biddle's list of the 76 dead (74 of yellow fever) aboard the USS Macedonian, dated 3 August 1822

The evolutionary origins of yellow fever most likely lie in Africa, with transmission of the disease from nonhuman primates to humans.[119][118] The virus is thought to have originated in East or Central Africa and spread from there to West Africa. As it was endemic in Africa, local populations had developed some immunity to it. When an outbreak of yellow fever would occur in an African community where colonists resided, most Europeans died, while the indigenous Africans usually developed nonlethal symptoms resembling influenza.[1] This phenomenon, in which certain populations develop immunity to yellow fever due to prolonged exposure in their childhood, is known as acquired immunity.[120] The virus, as well as the vector A. aegypti, were probably transferred to North and South America with the trafficking of slaves from Africa, part of the Columbian exchange following European exploration and colonization.[121] However, some researchers have argued that yellow fever might have existed in the Americas during the pre-Columbian period as mosquitoes of the genus Haemagogus, which is indigenous to the Americas, have been known to carry the disease.[122]

The first definitive outbreak of yellow fever in the New World was in 1647 on the island of Barbados.[123] An outbreak was recorded by Spanish colonists in 1648 in the Yucatán Peninsula, where the indigenous Mayan people called the illness xekik ("blood vomit"). In 1685, Brazil suffered its first epidemic in Recife. Dr. John Mitchell of Virginia made the first recorded mention of a disease by the name "yellow fever" in 1744.[124][125][126] However, Mitchell misdiagnosed the disease that he observed and treated, which was probably Weil's disease or hepatitis.[127]

McNeill argues that the environmental and ecological disruption caused by the introduction of sugar plantations created the conditions for mosquito and viral reproduction, and subsequent outbreaks of yellow fever.[128] Deforestation reduced populations of insectivorous birds and other creatures that fed on mosquitoes and their eggs.[129]

In Colonial times and during the Napoleonic Wars, the West Indies were known as a particularly dangerous posting for soldiers due to yellow fever being endemic in the area.[130] The mortality rate in British garrisons in Jamaica was seven times that of garrisons in Canada, mostly because of yellow fever and other tropical diseases.[131] Both English and French forces posted there were seriously affected by the "yellow jack".[132] Wanting to regain control of the highly profitable sugar trade on Hispaniola, and rejuvenate France's New World empire, Napoleon sent an army under the command of his brother-in-law General Charles Leclerc to Saint-Domingue to seize control after a slave revolt.[133] The historian J. R. McNeill asserts that yellow fever inflicted between 35,000 and 45,000 casualties on French army,[134] which was forced to withdraw, with only one-third surviving to return to France. Consequently, Napoleon abandoned his plans for North America and sold Louisiana to the US in 1803. In 1804, Haiti proclaimed its independence as the second republic in the Western Hemisphere.[135] Considerable debate exists over whether the number of deaths caused by disease in the Haitian Revolution was exaggerated.[136]

Although yellow fever is most prevalent in tropical-like climates, the northern United States was not exempt from the fever. The first outbreak in English-speaking North America occurred in New York City in 1668.[137] English colonists in Philadelphia and the French in the Mississippi River Valley recorded major outbreaks in 1669, as well as additional yellow fever epidemics in Philadelphia, Baltimore, and New York City in the 18th and 19th centuries. The disease traveled along steamboat routes from New Orleans, causing some 100,000–150,000 deaths in total.[138] The Yellow Fever Epidemic of 1793 in Philadelphia, which was then the capital of the United States, caused thousands of deaths totaling over 9% of the city's population,[139] including James Hutchinson, a physician helping to treat the population of the city. As the outbreak escalated organs of the federal government fled piecemeal to the city to Trenton, New Jersey, eventually being joined by President George Washington.[140] This was done with little coordination or formal sanction and at times was carried out in great haste. All entities of the federal government including Congress and President soon returned to resume operations in Philadelphia as the epidemic subsided. However, another severe outbreak in 1799 culminated in an official decision to relocate the national government to the city of Trenton, where it remained for the next six months.

The southern city of New Orleans was plagued with major epidemics during the 19th century, most notably in 1833 and 1853.[141] A major epidemic occurred in both New Orleans and Shreveport, Louisiana, in 1873. Its residents called the disease "yellow jack". Urban epidemics continued in the United States until 1905, with the last outbreak affecting New Orleans.[142][15][143]

At least 25 major outbreaks took place in the Americas during the 18th and 19th centuries, including particularly serious ones in Cartagena, Chile, in 1741; Cuba in 1762 and 1900; Santo Domingo in 1803; and Memphis, Tennessee, in 1878.[144]

In the early 19th century, the prevalence of yellow fever in the Caribbean "led to serious health problems" and alarmed the United States Navy as numerous deaths and sickness curtailed naval operations and destroyed morale.[145] One episode began in April 1822 when the frigate USS Macedonian left Boston and became part of Commodore James Biddle's West India Squadron. Unbeknownst to all, they were about to embark on an assignment that "would prove a cruise through hell".[146] Secretary of the Navy Smith Thompson had assigned the squadron to guard American merchant shipping and suppress piracy.[147] From 26 May to 3 August 1822, 76 of the Macedonian's officers and men died, including John Cadle, surgeon USN. 74 of these deaths were attributed to yellow fever. Biddle reported that another 52 of his crew were on the sick list. In their report to the secretary of the Navy, Biddle and Surgeon's Mate Charles Chase stated the cause as "fever". As a consequence of this loss, Biddle noted that his squadron was forced to return to Norfolk Navy Yard early. Upon arrival, the Macedonian's crew were provided medical care and quarantined at Craney Island, Virginia.[148][149][146]

In 1853, Cloutierville, Louisiana, had a late-summer outbreak of yellow fever that quickly killed 68 of the 91 inhabitants. A local doctor concluded that some unspecified infectious agent had arrived in a package from New Orleans.[150][151] In 1854, 650 residents of Savannah, Georgia, died from yellow fever.[152] In 1858, St. Matthew's German Evangelical Lutheran Church in Charleston, South Carolina, had 308 yellow fever deaths, reducing the congregation by half.[153] A ship carrying persons infected with the virus arrived in Hampton Roads in southeastern Virginia in June 1855.[154] The disease spread quickly through the community, eventually killing over 3,000 people, mostly residents of Norfolk and Portsmouth.[155] In 1873, Shreveport lost 759 citizens in an 80-day period to a yellow fever epidemic that began in August, by November over 400 additional victims succumbed for a total death toll of approximately 1,200.[156][157]

The widespread Lower Mississippi Valley yellow fever epidemic of 1878 caused an estimated 20,000 fatalities.[158] That year, Memphis had an unusually large amount of rain, which led to an increase in the mosquito population. The result was a huge epidemic of yellow fever.[159] The steamship John D. Porter took people fleeing Memphis northward in hopes of escaping the disease, but passengers were not allowed to disembark due to concerns of spreading yellow fever. The ship roamed the Mississippi River for the next two months before unloading her passengers.[160]

Major outbreaks have also occurred in southern Europe. Gibraltar lost many lives to outbreaks in 1804, 1814, and 1828.[161] Barcelona suffered the loss of several thousand citizens during an outbreak in 1821. The Duke de Richelieu deployed 30,000 French troops to the border between France and Spain in the Pyrenees Mountains, to establish a cordon sanitaire to prevent the epidemic from spreading from Spain into France.[162]

Causes and transmission

[edit]

Ezekiel Stone Wiggins, known as the Ottawa Prophet, proposed that the cause of a yellow fever epidemic in Jacksonville, Florida, in 1888, was astrological.[163]

The planets were in the same line as the sun and earth and this produced, besides Cyclones, Earthquakes, etc., a denser atmosphere holding more carbon and creating microbes. Mars had an uncommonly dense atmosphere, but its inhabitants were probably protected from the fever by their newly discovered canals, which were perhaps made to absorb carbon and prevent the disease.[164]

In 1848, Josiah C. Nott suggested that yellow fever was spread by insects such as moths or mosquitoes, basing his ideas on the pattern of transmission of the disease.[165] Carlos Finlay, a Cuban-Spanish doctor and scientist, proposed in 1881 that yellow fever might be transmitted by previously infected mosquitoes rather than by direct contact from person to person, as had long been believed.[166][167] Since the losses from yellow fever in the Spanish–American War in the 1890s were extremely high, U.S. Army doctors began research experiments with a team led by Walter Reed, and composed of doctors James Carroll, Aristides Agramonte, and Jesse William Lazear. They successfully proved Finlay's "mosquito hypothesis". Yellow fever was the first virus shown to be transmitted by mosquitoes. The physician William Gorgas applied these insights and eradicated yellow fever from Havana. He also campaigned against yellow fever during the construction of the Panama Canal. A previous effort of canal building by the French had failed in part due to mortality from the high incidence of yellow fever and malaria, which killed many workers.[15]

Although Reed has received much of the credit in United States history books for "beating" yellow fever, he had fully credited Finlay with the discovery of the yellow fever vector, and how it might be controlled. Reed often cited Finlay's papers in his articles and also credited him for the discovery in his correspondence.[168] The acceptance of Finlay's work was one of the most important and far-reaching effects of the U.S. Army Yellow Fever Commission of 1900.[169] Applying methods first suggested by Finlay, the United States government and Army eradicated yellow fever in Cuba and later in Panama, allowing completion of the Panama Canal. While Reed built on the research of Finlay, historian François Delaporte notes that yellow fever research was a contentious issue. Scientists, including Finlay and Reed, became successful by building on the work of less prominent scientists, without always giving them the credit they were due.[170] Reed's research was essential in the fight against yellow fever. He is also credited for using the first type of medical consent form during his experiments in Cuba, an attempt to ensure that participants knew they were taking a risk by being part of testing.[171]

Like Cuba and Panama, Brazil also led a highly successful sanitation campaign against mosquitoes and yellow fever. Beginning in 1903, the campaign led by Oswaldo Cruz, then director general of public health, resulted not only in eradicating the disease but also in reshaping the physical landscape of Brazilian cities such as Rio de Janeiro.[172] During rainy seasons, Rio de Janeiro regularly suffered floods, as water from the bay surrounding the city overflowed into Rio's narrow streets. Coupled with the poor drainage systems found throughout Rio, this created swampy conditions in the city's neighborhoods. Pools of stagnant water stood year-long in city streets and proved to be fertile ground for disease-carrying mosquitoes. Thus, under Cruz's direction, public health units known as "mosquito inspectors" fiercely worked to combat yellow fever throughout Rio by spraying, exterminating rats, improving drainage, and destroying unsanitary housing. Ultimately, the city's sanitation and renovation campaigns reshaped Rio de Janeiro's neighborhoods. Its poor residents were pushed from city centers to Rio's suburbs, or to towns found in the outskirts of the city. In later years, Rio's most impoverished inhabitants would come to reside in favelas.[173]

During 1920–1923, the Rockefeller Foundation's International Health Board undertook an expensive and successful yellow fever eradication campaign in Mexico.[174] The IHB gained the respect of Mexico's federal government because of the success. The eradication of yellow fever strengthened the relationship between the US and Mexico, which had not been very good in the years prior. The eradication of yellow fever was also a major step toward better global health.[175]

In 1927, scientists isolated the Yellow fever virus in West Africa.[176] Following this, two vaccines were developed in the 1930s. Max Theiler led the completion of the 17D yellow fever vaccine in 1937, for which he was subsequently awarded the Nobel Prize in Physiology or Medicine.[177] That vaccine, 17D, is still in use, although newer vaccines, based on vero cells, are in development (as of 2018).[4][178][179]

Current status

[edit]

Using vector control and strict vaccination programs, the urban cycle of yellow fever was nearly eradicated from South America.[180] Since 1943, only a single urban outbreak in Santa Cruz de la Sierra, Bolivia, has occurred. Since the 1980s, however, the number of yellow fever cases has been increasing again, and A. aegypti has returned to the urban centers of South America. This is partly due to limitations on available insecticides, as well as habitat dislocations caused by climate change. It is also because the vector control program was abandoned. Although no new urban cycle has yet been established, scientists believe this could happen again at any point. An outbreak in Paraguay in 2008 was thought to be urban in nature, but this ultimately proved not to be the case.[4]

In Africa, virus eradication programs have mostly relied upon vaccination.[181] These programs have largely been unsuccessful because they were unable to break the sylvatic cycle involving wild primates. With few countries establishing regular vaccination programs, measures to fight yellow fever have been neglected, making the future spread of the virus more likely.[4]

Research

[edit]

In the hamster model of yellow fever, early administration of the antiviral ribavirin is an effective treatment of many pathological features of the disease.[182] Ribavirin treatment during the first five days after virus infection improved survival rates, reduced tissue damage in the liver and spleen, prevented hepatocellular steatosis, and normalised levels of alanine aminotransferase, a liver damage marker. The mechanism of action of ribavirin in reducing liver pathology in Yellow fever virus infection may be similar to its activity in the treatment of hepatitis C, a related virus.[182] Because ribavirin had failed to improve survival in a virulent rhesus model of yellow fever infection, it had been previously discounted as a possible therapy.[183] Infection was reduced in mosquitoes with the wMel strain of Wolbachia.[184]

Yellow fever has been researched by several countries as a potential biological weapon.[185]

Notes

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Yellow fever

View on Grokipedia
from Grokipedia
Yellow fever is an acute mosquito-borne viral hemorrhagic disease caused by the yellow fever virus (YFV), a single-stranded RNA flavivirus endemic to tropical and subtropical regions of Africa and the Americas.[1][2][3] Transmission occurs primarily through the bites of infected Aedes and Haemagogus species mosquitoes, which acquire the virus from infected humans or non-human primates in sylvatic cycles before propagating urban transmission.[4][2] The clinical course ranges from asymptomatic or mild febrile illness resembling influenza, affecting most infections, to severe toxic phase in 15-25% of symptomatic cases, featuring jaundice, renal failure, hemorrhage, and shock, with case-fatality rates of 20-50%.[5][3] No specific antiviral treatment exists; management is supportive, emphasizing hydration and symptom control.[5] A safe, effective live-attenuated vaccine, first developed in the 1930s from the attenuated 17D strain, confers lifelong immunity after a single dose and remains the primary preventive measure, averting epidemics through mass vaccination campaigns.[6][2] Despite vaccination efforts, yellow fever causes an estimated 67,000-173,000 severe cases and 31,000-82,000 deaths annually, mostly in unvaccinated populations in Africa, with resurgence risks from deforestation, urbanization, and vaccine hesitancy amplifying sylvatic-to-urban spillover.[2] Historical epidemics, such as those devastating 19th-century port cities, underscored mosquito vector control's role, validated by Walter Reed's experiments proving arthropod transmission over contaminated goods.[6] Ongoing challenges include vaccine supply constraints and rare adverse events like viscerotropic disease in vaccinees, though benefits far outweigh risks in endemic zones.[7][2]

Etiology and Transmission

Causative Agent

The causative agent of yellow fever is the yellow fever virus (YFV), an enveloped, positive-sense single-stranded RNA virus classified in the genus Flavivirus of the family Flaviviridae.[8] YFV serves as the prototype species for the genus and shares close phylogenetic relationships with other notable flaviviruses, including dengue virus and Zika virus, due to conserved genomic and structural features.[9] The virion is spherical, approximately 40-50 nm in diameter, with a lipid envelope derived from host cell membranes surrounding an icosahedral nucleocapsid core.[10] The YFV genome consists of a single open reading frame of about 10,862 nucleotides, flanked by untranslated regions, encoding a polyprotein precursor of roughly 3,433 amino acids. This polyprotein undergoes co- and post-translational cleavage by viral and host proteases to yield three structural proteins—capsid (C), premembrane/membrane (prM/M), and envelope (E)—and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) essential for replication and modulation of host responses. The envelope protein E facilitates viral attachment and entry via receptor-mediated endocytosis, while NS5 functions as the RNA-dependent RNA polymerase driving genome replication.[8] YFV exists as a single antigenic serotype, conferring lifelong immunity following infection, though genetic variation manifests in seven distinct genotypes reflecting geographic origins: two West African (genotypes I and II), East African, East/Central African, Angolan, and two South American (genotypes I and II).[11] These lineages arose from an African origin, with South American strains introduced via historical slave trade routes, and exhibit nucleotide divergence supporting enzootic maintenance in non-human primate reservoirs.[12] As an RNA virus, YFV demonstrates a relatively high mutation rate, on the order of 10^{-4} substitutions per site per year, enabling adaptation while preserving overall genetic stability across lineages.[13] The virus maintains zoonotic cycles primarily among Old World and New World primates in tropical forests of Africa and the Americas, underscoring its sylvatic evolutionary history.[14]

Transmission Cycles

Yellow fever virus (YFV) maintains three primary transmission cycles: sylvatic (jungle), intermediate (savannah), and urban, each defined by distinct ecological interactions between the virus, mosquito vectors, and vertebrate hosts.[4][15] The sylvatic cycle predominates in forested regions of tropical Africa and South America, where Haemagogus species (in the Americas) or certain Aedes species (such as Aedes africanus in Africa) serve as enzootic vectors, transmitting YFV between non-human primates like howler monkeys or chimpanzees as reservoir hosts.[16][17] Humans become incidental hosts through spillover when entering these habitats, such as via forestry activities, with mosquito bites delivering the virus during the host's brief viremic period of 3-6 days post-infection.[4] This cycle requires dense canopy forests with high humidity and temperatures above 20°C for mosquito survival and replication, limiting endemicity to equatorial zones.[18] ![Aedes aegypti feeding on human][float-right] The intermediate cycle occurs in Africa's savannah regions, bridging sylvatic and human populations through anthropophilic mosquitoes like Aedes luteocephalus, which feed on both primates and humans in semi-rural areas with partial forest clearance.[19] Here, infected primates amplify transmission to humans encroaching on these edges, but without sustained human-to-human spread, as YFV lacks direct human transmissibility absent a vector; no documented cases exist of non-vector-mediated human-to-human transfer.[20] This cycle depends on ecological interfaces where vector biting preferences shift toward humans due to proximity, sustaining low-level endemicity in transitional landscapes.[21] The urban cycle, absent in the Americas since 1942 but persistent in parts of Africa, relies on Aedes aegypti as the domestic vector, which preferentially bites humans during daylight hours and breeds in artificial water containers, facilitating amplification among unvaccinated populations in densely populated areas.[22] Transmission initiates from sylvatic spillover into urban peripheries, then propagates human-to-mosquito-to-human without primate involvement, requiring viremic humans (incubation 3-6 days) to infect feeding females whose eggs transmit vertically at low rates.[4] Urban endemicity demands year-round vector habitat from standing water and temperatures supporting extrinsic incubation periods of 9-15 days.[19] Deforestation and road construction fragment forests, increasing edge habitats that boost vector density and host contact, thereby elevating spillover risk from sylvatic to intermediate or urban cycles through heightened mosquito dispersal along linear features.[23] Urbanization exacerbates this by concentrating susceptible humans near enzootic foci, overriding natural barriers like dense forest interiors that limit vector range, though such dynamics stem from habitat alteration rather than isolated climatic shifts.[24][25] These cycles remain vector-dependent, with no evidence of airborne or fomite transmission.[26]

Pathophysiology

Viral Replication and Host Interaction

Yellow fever virus (YFV), a member of the genus Flavivirus, initiates infection by binding to host cell surface receptors, primarily DC-SIGN (dendritic cell-specific ICAM-3-grabbing non-integrin) on dendritic cells and other attachment factors like G protein-coupled receptor kinase 2 (GRK2), facilitating clathrin-mediated endocytosis.[27][28] Following endocytosis, low pH in the endosome triggers fusion of the viral envelope with the endosomal membrane, releasing the positive-sense single-stranded RNA genome into the cytoplasm.[29] The genomic RNA is then translated into a single polyprotein that is cleaved by viral and host proteases into structural (capsid, prM/M, envelope) and non-structural (NS1–NS5) proteins, with replication occurring on endoplasmic reticulum-derived membranes in the cytoplasm.[30] Viral replication predominantly targets reticuloendothelial tissues, including regional lymph nodes for initial amplification in dendritic cells and macrophages, followed by dissemination to the liver (hepatocytes and Kupffer cells), spleen, and bone marrow.[30][31] In the liver, YFV exploits hepatocytes for high-titer progeny production, with empirical studies in nonhuman primates showing peak viral loads reaching 10^6–10^8 plaque-forming units per gram of tissue by days 3–5 post-infection, enabling systemic spread before peak innate immune activation.[32] This viscerotropic tropism arises from the virus's adaptation to myeloid-lineage cells, where NS proteins rearrange host membranes to form replication complexes shielded from cytosolic sensors.[33] YFV evades early innate immunity by antagonizing type I interferon (IFN) signaling, primarily through NS5-mediated degradation of STAT2, a key transducer in the JAK-STAT pathway, which suppresses IFN-stimulated gene expression and permits unchecked replication in IFN-producing cells like dendritic cells.[34] This mechanism delays antiviral responses for 2–3 days, correlating with observed viral load surges in lymph nodes and plasma during experimental infections, where untreated hosts exhibit 10- to 100-fold higher dissemination compared to IFN-pretreated models.[35] Empirical quantification in rhesus macaques confirms that NS5 inhibition sustains viral RNA synthesis rates of up to 10^4 genomes per infected cell per replication cycle, outpacing initial IFN induction.[36] Genetic adaptations distinguish African and South American YFV lineages, with West African genotypes (e.g., genotype I) exhibiting greater sequence diversity and potentially higher intrinsic virulence due to enzootic cycling in primate reservoirs, while South American genotypes (e.g., genotype IX), derived via transatlantic bottlenecks around 300–500 years ago, show adaptive mutations in envelope and NS genes that modulate receptor binding and replication efficiency.[37][38] For instance, South American strains display reduced neuroinvasiveness in rodent models, attributed to single-residue variations in the envelope protein that alter endosomal fusion kinetics, though viscerotropic lethality remains comparable; these differences reflect host-switching pressures rather than uniform attenuation.[39][10]

Mechanisms of Tissue Damage

The hallmark of severe yellow fever pathology is midzonal necrosis of hepatocytes in the liver, where the virus targets the midzone of liver lobules, inducing apoptosis, necrosis, and steatosis without significant inflammation or viral inclusions. This pattern, observed in autopsy examinations of fatal cases, spares periportal and centrilobular regions initially, leading to Councilman bodies (apoptotic hepatocytes) and microvesicular fat accumulation, which impair bilirubin conjugation and excretion, manifesting as jaundice—the eponymous feature of the disease.[40][41][42] Hepatic dysfunction from this necrosis depletes synthesis of procoagulant factors (such as factors II, V, VII, IX, and X), resulting in hypocoagulability and hemorrhagic diathesis, independent of widespread consumptive mechanisms like disseminated intravascular coagulation. Cohort studies of severe cases demonstrate profoundly low levels of these liver-derived factors correlating directly with bleeding severity, distinguishing yellow fever coagulopathy from endothelial-driven consumption seen in other viral hemorrhagic fevers.[43][44] Endothelial infection exacerbates multi-organ failure through vascular leakage and dysfunction; yellow fever virus productively infects endothelial cells, upregulating adhesion molecules and proinflammatory cytokines, which promote prothrombotic states, hemorrhage, and shock. Elevated circulating nonstructural protein 1 (NS1) and syndecan-1 levels in severe disease reflect this endothelial glycocalyx degradation, contributing to plasma extravasation, renal tubular necrosis, and myocardial injury observed in autopsies. An associated cytokine storm, with surges in IL-6, TNF-α, and IFN-γ, amplifies hepatocyte toxicity and systemic inflammation, driving progression to terminal multi-organ collapse.[45][46][47] Host genetic variation modulates susceptibility to these mechanisms; 19th-century epidemic data from the United States reveal case-fatality rates as low as 4.5% among individuals of African ancestry versus over 20% in Caucasians, attributable to heritable factors rather than acquired immunity or socioeconomic differences, underscoring innate genetic influences on viral clearance and tissue resilience over purely environmental explanations.[48]

Clinical Manifestations

Incubation Period and Mild Disease

The incubation period for yellow fever virus infection is typically 3 to 6 days after the bite of an infected mosquito, during which the virus replicates systemically without overt clinical signs.[5][2][3] This period reflects the time required for sufficient viral propagation to trigger host immune responses, with rare extensions to 9 days in documented cases.[49] A substantial proportion of infections—estimated at 50% to 85% based on serological surveys and outbreak data—remain subclinical, with no detectable symptoms or only minor viremia insufficient to cause illness.[50][7][3] Among symptomatic cases, approximately 85% manifest as mild, self-limited disease, lacking progression to hepatic or hemorrhagic complications.[2][3] These presentations typically begin abruptly with high fever (often exceeding 38.5°C), chills, severe headache, myalgia, arthralgia, and malaise, resembling undifferentiated viral febrile illnesses.[51][52] Empirical data from case series in endemic regions, such as controlled studies during urban outbreaks, confirm resolution within 3 to 4 days without jaundice, bleeding, or organ dysfunction, driven by effective innate immune clearance rather than viral persistence.[51][52][3] The mild phase corresponds to the initial viremic period, where symptoms subside as neutralizing antibodies emerge, preventing escalation observed in severe forms; this distinction correlates with lower peak viral loads (often below 10^6 RNA copies/mL in mild cases) and robust interferon responses, as evidenced by longitudinal virologic studies.[50][3] Patients generally recover fully without sequelae, though fatigue may linger briefly; historical case series from non-vaccinated cohorts in Africa and South America underscore this non-fatal trajectory in the absence of comorbidities or high-dose exposure.[52][50]

Severe Form and Complications

Approximately 15% of symptomatic yellow fever cases progress to a severe toxic phase, typically 24 hours after apparent remission of initial symptoms.[53] This phase features resurgence of high fever, relative bradycardia, jaundice due to hepatic involvement, hemorrhagic manifestations such as petechiae, ecchymoses, epistaxis, and gastrointestinal bleeding, oliguria progressing to renal failure, and hypotension leading to shock.[3] [7] Complications in the toxic phase include multiorgan dysfunction, with prominent hepatic necrosis, coagulopathy from disseminated intravascular coagulation, and encephalopathy manifesting as delirium, seizures, or coma.[54] Secondary bacterial infections, such as pneumonia or sepsis, can exacerbate outcomes due to immunosuppression and prolonged hospitalization.[3] Autopsy findings consistently reveal midzonal hepatocellular necrosis, Councilman bodies (apoptotic hepatocytes), and steatosis in the liver, alongside renal tubular necrosis and myocardial involvement in fatal cases.[54] 00376-6/fulltext) The case-fatality rate in severe cases ranges from 20% to 60%, with deaths often occurring within 7-10 days from multiorgan failure; untreated rates historically approached 80% in epidemics lacking supportive care.[2] [7] [55] In sylvatic outbreak settings, severe cases disproportionately affect males due to occupational exposure in forested areas, such as forestry work or rural activities increasing contact with vector mosquitoes and primate reservoirs.[56] [57] Survivors of the toxic phase undergo a prolonged convalescent period of weeks to months, marked by asthenia and potential viral persistence in tissues, though most achieve full recovery without chronic organ impairment; persistent immune alterations, such as altered T-cell responses, have been observed in some but lack consistent long-term clinical sequelae in population studies.[58]

Diagnosis

Clinical Assessment

Clinical assessment of suspected yellow fever begins with a detailed history emphasizing travel to or residence in endemic areas of sub-Saharan Africa or South America, particularly during peak transmission seasons from January to October in Africa and December to May in the Americas.[51] Exposure to Aedes or Haemagogus mosquitoes, lack of vaccination, and symptom onset 3-6 days post-exposure are critical indicators, as the incubation period typically ranges from 3 to 6 days.[51] [59] Initial symptoms such as sudden fever, headache, myalgias, and nausea prompt suspicion, especially in unvaccinated travelers returning from at-risk regions.[2] Physical examination reveals characteristic findings in early disease, including relative bradycardia disproportionate to the fever (Faget's sign), conjunctival injection, and facial flushing.[52] [60] Hepatomegaly may be present due to hepatic involvement, alongside potential mild jaundice in progressing cases.[3] The patient often appears acutely ill, with these signs aiding differentiation from other febrile illnesses.[51] According to World Health Organization criteria, a suspected case is defined as any person with acute onset of fever followed by jaundice within 14 days of symptom onset.[61] The Centers for Disease Control and Prevention specifies acute illness with fever, jaundice, or elevated total bilirubin ≥3 mg/dL, absent a more likely explanation.[49] Probable cases include suspected presentations with supportive epidemiologic links, such as IgM positivity without recent vaccination.[62] Differential diagnosis includes dengue, malaria, and leptospirosis, which share fever, jaundice, and hemorrhagic features but differ in epidemiology and specific signs; for instance, malaria lacks relative bradycardia, while leptospirosis often involves conjunctival suffusion and renal failure.[63] [2] Travel history and absence of mosquito avoidance help distinguish yellow fever, though overlap necessitates prompt exclusion of treatable mimics like malaria via history and exam before confirmatory testing.[3]

Laboratory Confirmation

Laboratory confirmation of yellow fever virus (YFV) infection primarily relies on detection of viral nucleic acids during the acute phase or serological evidence of immune response in later stages. Reverse transcription polymerase chain reaction (RT-PCR) assays target YFV RNA in serum or plasma collected within the first 3-5 days of symptom onset, offering high sensitivity for viremic patients.[51] Quantitative real-time RT-PCR protocols, such as those validated against reference strains, achieve detection limits as low as 10-100 genome copies per reaction and demonstrate near-100% specificity across African and South American lineages when designed with conserved primers.[64] Field evaluations in outbreaks confirm RT-PCR sensitivity exceeding 90% in early acute samples compared to virus isolation, though false negatives may occur post-day 5 as viremia declines.[65] Virus isolation in cell culture (e.g., Vero or C6/36 cells) or suckling mice provides definitive proof but is infrequently performed due to the requirement for Biosafety Level 3 (BSL-3) facilities and enhanced personal protective equipment, given YFV's aerosol transmission risk and potential for laboratory-acquired infection.[66] Isolation success rates drop rapidly after fever onset, mirroring viremia kinetics, and are thus supplementary to molecular methods rather than routine.[64] Serological testing detects YFV-specific IgM antibodies via enzyme-linked immunosorbent assay (ELISA), typically appearing by days 5-10 post-onset and persisting for 30-90 days, providing presumptive diagnosis in non-viremic convalescent samples.[67] However, IgM ELISAs exhibit cross-reactivity with other flaviviruses such as dengue and Zika, yielding specificities as low as 70-80% in endemic areas with co-circulating pathogens, necessitating confirmatory plaque reduction neutralization tests (PRNT) that measure neutralizing antibodies at 90% reduction thresholds for lineage-specific identification.[64] PRNT, performed in BSL-3 labs, distinguishes YFV from heterologous flaviviruses with >90% accuracy but requires paired acute-convalescent sera for seroconversion evidence.[66] In fatal cases, post-mortem diagnosis employs immunohistochemistry (IHC) on formalin-fixed liver, kidney, or heart tissues to detect YFV antigens in midzonal hepatocytes exhibiting Councilman bodies and steatosis, with reported sensitivities of 85-95% in autopsy series from outbreaks when combined with RT-PCR on tissue extracts.[67] IHC specificity approaches 100% using monoclonal antibodies against viral envelope proteins, outperforming histopathology alone in resource-limited settings, though autolysis can reduce yield if delays exceed 24 hours.[68] Integrated approaches, including minimally invasive autopsies, enhance diagnostic yield in surveillance without full dissection.[69]

Management and Treatment

Supportive Therapy

There is no specific antiviral treatment for yellow fever, with management relying entirely on supportive therapy to address symptoms and prevent complications.[70][2] Mild cases are typically managed with rest, oral hydration, and analgesics such as acetaminophen for fever and pain, while avoiding agents that exacerbate hemorrhage.[70][71] Severe cases, characterized by jaundice, renal failure, or hemorrhagic manifestations, necessitate prompt hospitalization and intensive care unit (ICU) admission for aggressive fluid resuscitation, electrolyte correction, and monitoring for hypovolemia, oliguria, hypoxia, and acidosis.[71][3] Intravenous fluids are prioritized to maintain hemodynamic stability, often alongside vasoactive medications, mechanical ventilation for respiratory failure, and renal replacement therapy as needed.[71] Aspirin and nonsteroidal anti-inflammatory drugs must be avoided due to heightened bleeding risk from coagulopathy and thrombocytopenia.[70][72] Transfusions of fresh frozen plasma or platelets may be administered for disseminated intravascular coagulation or severe hemorrhage.[71] Empirical evaluations of antivirals, including ribavirin, have demonstrated no survival benefit in human or primate models of yellow fever, leading to their exclusion from standard protocols.[73] Early ICU intervention has been associated with mortality reductions; for instance, case fatality rates in severe cases average 39%, but can exceed 40% in South American outbreaks compared to variable rates (10-86%) in African cohorts, where limited access to advanced care contributes to higher untreated lethality.[74][75][76] Consensus guidelines emphasize rapid identification and organ support to mitigate multiorgan failure, though outcomes remain poor without vaccination.[77][78]

Antiviral and Experimental Approaches

No specific antiviral therapy is approved for yellow fever virus (YFV) infection, with management relying on supportive care amid ongoing research into investigational agents.[2] Experimental approaches primarily target viral replication through monoclonal antibodies (mAbs) and nucleoside analogs, informed by YFV's flavivirus classification and shared mechanisms with pathogens like hepatitis C virus (HCV) and dengue virus (DENV). Preclinical models demonstrate efficacy for select candidates, yet translation to human trials remains constrained by the disease's sporadic outbreaks, ethical barriers to randomization in high-mortality settings, and challenges in achieving flavivirus-specific potency without off-target effects.[79] Neutralizing mAbs have shown prophylactic and therapeutic potential in animal models of lethal YFV challenge. For instance, administration of human-derived mAbs targeting the virus envelope protein reduced mortality in hamsters when given post-exposure, highlighting epitope-specific neutralization as a viable mechanism.[80] A phase 1 trial of TY014, a fully human IgG1 mAb, confirmed safety and favorable pharmacokinetics in healthy volunteers but did not assess efficacy due to the absence of active infection.[81] Broader flaviviral mAb efforts, including those cross-reactive with YFV, face hurdles in specificity, as broad-spectrum candidates often exhibit diminished potency against divergent strains, underscoring the need for YFV-tailored development.[82] Nucleoside analogs, such as sofosbuvir—an NS5B polymerase inhibitor approved for HCV—exhibit in vitro and in vivo inhibition of YFV replication by depleting viral RNA synthesis. In Syrian hamster models, sofosbuvir reduced viremia and liver pathology when administered early post-infection. Compassionate-use cases in Brazil involved off-label sofosbuvir for severe YFV with acute liver failure, correlating with viremia decline and clinical stabilization in two patients, though causality remains unestablished absent controls. A 2024 observational study of 21 hospitalized Brazilian patients treated with sofosbuvir reported reduced genomic load but highlighted confounding factors like concurrent supportive measures, advocating randomized trials to confirm benefits. Other analogs, including galidesivir, entered phase 1 evaluation for YFV pharmacokinetics and antiviral effects, yet progression stalled amid recruitment difficulties tied to outbreak unpredictability.[83][84][85] Development faces systemic obstacles: YFV's rarity—fewer than 200,000 annual cases, mostly mild—yields insufficient severe cases for powered phase II/III trials, compounded by ethical concerns over withholding potential therapies in resource-poor endemic regions. Past broad-spectrum flaviviral candidates, like chloroquine analogs tested in dengue, demonstrated preclinical promise but faltered clinically due to inadequate specificity and host interferon interference, mirroring risks for YFV agents. These factors prioritize preclinical validation over premature optimism, with no candidates advancing beyond early phases as of 2025.[79][86]

Prevention Strategies

Vaccination Programs

Vaccination programs against yellow fever rely on the live-attenuated 17D vaccine, administered as a single dose that confers lifelong protection for over 99% of recipients, serving as the cornerstone of global prevention efforts.[87][88] The World Health Organization (WHO) integrates routine immunization into national schedules in 36 endemic African countries and 13 in the Americas, targeting infants aged 9-12 months to build population-level immunity and reduce urban transmission risks.[87] Preventive mass campaigns vaccinate at-risk populations before outbreaks, while reactive campaigns respond to confirmed cases, often achieving coverage rates exceeding 80% in targeted areas to interrupt transmission.[89] The Eliminate Yellow Fever Epidemics (EYE) initiative, launched in 2017 by WHO, Gavi, UNICEF, and the vaccine industry, coordinates vaccination across 40 high-risk countries in Africa and the Americas through over 50 partners, emphasizing surveillance, stockpiling, and rapid deployment.[90] By the end of 2023, Gavi-supported campaigns had reached more than 274 million children and adults in 18 countries, contributing to a decline in reported cases in supported regions.[91] The International Coordinating Group (ICG) maintains a global emergency stockpile of 6 million doses annually, funded by Gavi, to facilitate outbreak responses; during shortages, such as the 2016 Angola epidemic with over 3,800 cases and 369 deaths, fractional dosing (one-fifth of a standard dose) has been employed subcutaneously, demonstrating comparable short-term immunogenicity while extending supply.[87][89] Under the International Health Regulations (2005), approximately 34 countries in Africa and 12 in South America require an International Certificate of Vaccination or Prophylaxis (ICVP) as proof of yellow fever immunization for entry, particularly from endemic areas; certificates become valid 10 days post-vaccination and, following a 2016 WHO policy update, are considered lifelong without boosters for international travel purposes.[92][7][93] WHO/UNICEF estimates administrative vaccination coverage in endemic countries varies, with many African nations reporting 45-94% for first doses as of recent years, underscoring ongoing challenges in achieving herd immunity thresholds amid logistical barriers.[94][95] Mass campaigns have proven effective in averting outbreaks; modeling indicates that vaccinations conducted up to 2013 prevented 22-31% of potential cases and deaths in Africa, highlighting the causal impact of high coverage on reducing incidence in urbanizing endemic zones.[96] Programs emphasize integrated surveillance with vaccination, as sustained immunity gaps in sylvatic cycles necessitate complementary vector control, though vaccination alone has contained major epidemics like those in Angola and Brazil.[97][89]

Vaccine Development and Efficacy

The yellow fever vaccine was developed by Max Theiler at the Rockefeller Institute for Medical Research in the 1930s. Starting from the Asibi strain of the virus isolated in 1927, Theiler attenuated it through serial passages in mouse embryonic tissue followed by chick embryo tissue, yielding the 17D strain in 1937, which proved safe and immunogenic in humans.[98][99] This live attenuated vaccine was first administered widely during World War II to protect troops, demonstrating field effectiveness in preventing outbreaks.[100] Two primary substrains, 17D-204 and 17DD, emerged from parallel derivations of the 17D virus in the 1930s and are used interchangeably for production in embryonated chicken eggs. The 17D-204 strain underwent additional passages to enhance stability, while 17DD was developed in Brazil with a distinct passage history; both elicit comparable humoral and cellular immune responses, including neutralizing antibodies and T-cell activation.[101][102] Clinical and epidemiological data indicate high efficacy, with seroconversion rates exceeding 99% in healthy adults after a single dose, conferring protection against severe disease.[103] Although the original vaccine lacked modern phase III trials, observational studies and challenge models show very low breakthrough infection rates, with fewer than 1% of primary vaccinees experiencing infection upon exposure, supporting lifelong immunity in most individuals without need for boosters.[104][105] The World Health Organization endorses a single dose for lifelong protection, estimating it prevents 31,000–82,000 deaths annually in endemic areas.[2] Recent trials confirm immunogenicity persists for decades, though subtle waning of antibodies occurs in some populations, particularly older adults or those with comorbidities, without correlating to increased disease risk.[105]

Safety Profile and Rare Adverse Events

The yellow fever 17D vaccine exhibits a robust safety profile, with mild adverse reactions such as injection-site pain, fever, headache, and myalgia occurring in approximately 10-30% of recipients, typically resolving within days without intervention.[106] Serious adverse events remain exceedingly rare, estimated at less than 5 per million doses administered, based on surveillance data from large-scale campaigns involving hundreds of millions of vaccinations since the 1930s.[107] These events predominantly affect primary vaccinees, with risk factors including advanced age (over 60 years), thymic disorders, and possibly genetic predispositions, though causality for the latter requires further confirmation.[108] Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) manifests as disseminated infection mimicking severe wild-type yellow fever, characterized by high viremia, hepatic and renal failure, coagulopathy, and shock, with onset 3-10 days post-vaccination. Incidence rates are approximately 0.3-0.4 cases per 100,000 doses overall, rising to 1-2 per 100,000 in individuals aged 60 and older, and fatality rates range from 20-60% in reported cases.[109] [110] All documented YEL-AVD instances have occurred after first-time immunization, with no confirmed cases following boosters, underscoring the vaccine's attenuated nature but highlighting potential over-attenuation failure in susceptible hosts.[107] Yellow fever vaccine-associated neurotropic disease (YEL-AND), resembling encephalitis or Guillain-Barré syndrome, presents with fever, headache, altered mental status, and focal neurologic deficits, typically emerging 5-21 days after vaccination. Reported incidence is about 0.2-0.8 per 100,000 doses, with higher estimates (up to 2.3 per 100,000) in some mass campaigns, and a case-fatality rate of around 15%, though most survivors experience residual neurologic impairment.[111] [112] These events are distinguished from wild virus infection by genetic analysis confirming vaccine-strain RNA in affected tissues.[113] Hypersensitivity reactions, including anaphylaxis and urticaria, occur at rates of roughly 1-2 per 100,000 doses, often linked to egg proteins in the vaccine production process, though fractionated doses have mitigated risks in egg-allergic individuals under medical supervision.[114] Post-vaccination monitoring for 10 days is recommended, particularly in at-risk groups, with contraindications encompassing immunodeficiency, infancy under 6 months, and active malignancy to avert these rare but severe outcomes.[106] Ongoing pharmacovigilance through systems like VAERS confirms the vaccine's favorable risk-benefit ratio in endemic areas, where disease mortality exceeds 20-50%.[112]

Controversies and Public Hesitancy

The yellow fever vaccine, a live-attenuated strain (17D-204 or equivalent), has been associated with rare but serious adverse events that have sparked controversies regarding its risk-benefit profile, particularly for non-endemic travelers or low-risk populations. These include yellow fever vaccine-associated viscerotropic disease (YEL-AVD), which mimics severe yellow fever with multi-organ failure and a case-fatality rate exceeding 50%, and yellow fever vaccine-associated neurotropic disease (YEL-AND), resembling acute viral encephalitis. Incidence rates for YEL-AVD are estimated at 0.3–0.4 cases per 100,000 doses overall, rising to 1.8–11.3 per 100,000 in individuals over 60 years old receiving their first dose. YEL-AND occurs at approximately 0.1–0.2 per 100,000 doses, with similar age-related increases. Anaphylaxis, another rare hypersensitivity reaction, affects about 1 in 130,000 doses. These events, documented in surveillance systems like the U.S. Vaccine Adverse Event Reporting System (VAERS), have led to contraindications for infants under 6 months, immunocompromised persons, and those with thymus disorders, prompting debates on mandatory vaccination for travel despite low transmission risk in some destinations.[108][103][107] Public hesitancy toward the vaccine stems primarily from awareness of these adverse events, compounded by misinformation, perceived low personal risk of yellow fever, and logistical barriers. Surveys in endemic regions like Brazil reveal that fear of side effects, including mild reactions like fever and myalgia (affecting up to 30% of recipients), is a leading barrier, alongside distrust in vaccine safety and time constraints for immunization. In Uganda, during 2024 vaccination drives, hospitals reported hundreds of unused doses due to hesitancy driven by unfamiliarity with yellow fever—fewer visible cases compared to diseases like malaria—and rumors of severe reactions, despite the disease's lethality in unvaccinated populations. Similar patterns emerged in Colombia's 2023 outbreak response, where myths about vaccine-induced illness required targeted education to boost uptake from below 50% to over 80% in affected areas.[115][116][117] Hesitancy is amplified among travelers and expatriates, where the vaccine's lifelong immunity is weighed against rare risks without immediate disease threat, leading to requests for waivers that may invalidate travel documents under International Health Regulations. The COVID-19 pandemic exacerbated this by disrupting routine campaigns and eroding trust in health authorities, contributing to coverage gaps in at-risk zones. Despite these concerns, epidemiological data affirm the vaccine's net benefit in preventing outbreaks, with over 99% efficacy and billions of doses administered safely since 1937, though ongoing surveillance underscores the need for risk stratification, such as fractional dosing in shortages, to mitigate hesitancy without compromising control efforts.[118][119][108]

Vector Management

Vector management for yellow fever focuses on controlling Aedes aegypti mosquitoes through integrated approaches prioritizing habitat modification and chemical interventions over novel technologies. Source reduction, which entails eliminating or treating artificial water-holding containers like tires, drums, and flower pots that serve as breeding sites, forms the cornerstone of these efforts, as A. aegypti thrives in urban domestic environments.[120] Larvicides, such as organophosphates like temephos, are applied to unavoidable water collections to kill immature stages, while adult mosquito control involves ultra-low volume (ULV) space spraying of pyrethroid insecticides like deltamethrin during outbreaks to reduce biting populations.[50] These methods emphasize sustained, low-cost actions tailored to local ecology rather than high-tech releases, which often face scalability issues in endemic regions. Historical campaigns demonstrate the potential efficacy of rigorous vector control. In Brazil, a national eradication program launched in the 1940s successfully eliminated A. aegypti from most urban areas by 1958 through house-to-house inspections, source elimination, and larviciding, halting urban yellow fever transmission that had persisted into the early 20th century.[121] This effort, coordinated by the Brazilian Ministry of Health with international support, certified the country as mosquito-free in key zones, correlating with zero urban yellow fever cases reported since the 1940s.[122] Similar programs across the Americas reduced A. aegypti prevalence, underscoring that comprehensive, labor-intensive source reduction can achieve near-elimination when consistently applied. Insecticide resistance, however, undermines chemical controls, particularly pyrethroids, which comprise the majority of adulticides used globally. By 2023, widespread resistance to deltamethrin and permethrin was documented in A. aegypti populations across Africa, Asia, and the Americas, driven by kdr mutations and metabolic detoxification, reducing spray efficacy by factors of 10-100 in some sites.[123][124] This resistance, accelerated by routine use in dengue and malaria programs, necessitates rotation of insecticide classes and integration with non-chemical methods to maintain control, as standalone spraying fails against resilient vectors.[125] Community-driven initiatives often outperform centralized, top-down campaigns by fostering local ownership and sustained compliance. Participatory source reduction programs, where residents actively remove breeding sites, have shown superior long-term mosquito density reductions compared to vertical spraying alone, with meta-analyses of arboviral vector control indicating up to 50% greater effectiveness in urban settings through behavioral change.[126] In yellow fever-endemic areas, such approaches link directly to lower transmission risk, as evidenced by reduced A. aegypti indices in community-led efforts in Burkina Faso analogs, where engagement halved larval habitats versus expert-only interventions.[127] This causal mechanism—enhanced surveillance and maintenance by locals—addresses the reinfestation common after eradication drives, promoting resilience without relying on external funding.[128]

Public Health Measures

Public health measures for yellow fever emphasize early detection through integrated surveillance systems, including sentinel sites and laboratory networks in endemic regions, to enable prompt outbreak response.[2] The World Health Organization (WHO) recommends that high-risk countries maintain at least one national laboratory capable of yellow fever virus testing via polymerase chain reaction or serological methods, with all suspected cases investigated and confirmed rapidly to assess transmission risk.[2] Under the International Health Regulations (2005), member states must report confirmed yellow fever cases as potential public health emergencies of international concern, facilitating coordinated global responses through rapid response teams deployed for contact tracing, case isolation, and emergency vaccination campaigns.[129] These teams, often supported by WHO's Eliminate Yellow Fever Epidemics (EYE) initiative, have contained outbreaks by achieving high vaccination coverage in affected areas, as demonstrated in responses where early intervention reduced case numbers by over 90% in targeted zones.[130] To prevent international spread, countries enforce traveler requirements under the International Health Regulations, mandating proof of yellow fever vaccination via the International Certificate of Vaccination or Prophylaxis (ICVP, or "yellow card") for entry from endemic areas, valid for life following a single dose administered at least 10 days prior.[92] Exemptions are permitted for medical contraindications, documented by authorized health professionals, but non-compliance can result in denied entry or quarantine upon arrival.[2] Public education campaigns promote personal protective measures, such as insect repellents containing DEET and use of bed nets, integrated into travel advisories issued by bodies like the Centers for Disease Control and Prevention (CDC), which specify risk zones without overstating threats in low-transmission areas.[7] In vaccine shortages, fractional dosing—administering one-fifth (0.1 mL) of the standard 17D vaccine dose intradermally—has preserved herd immunity during outbreaks, as implemented by WHO in the 2016 Angola epidemic affecting over 7 million people, where it induced seroprotection in 97% of recipients persisting up to 5 years.[131] Studies confirm fractional doses elicit comparable neutralizing antibody responses to full doses for short-term outbreak control, enabling vaccination of up to five times more individuals and averting thousands of cases when full-dose supplies are limited.[132] This approach, restricted to emergencies by WHO guidelines, underscores adaptive strategies that maintain efficacy without compromising safety profiles observed in full dosing.[133]

Epidemiology

Global Burden and Distribution

Yellow fever imposes a substantial global disease burden, with recent estimates indicating 67,000–173,000 severe infections and 31,000–82,000 deaths annually in Africa and the Americas, predominantly in Africa.[2] Updated modeling from 1990 to 2021 shows a decline in cases and deaths, yet underreporting persists due to surveillance gaps and diagnostic limitations in endemic regions.[134] Approximately 90-92% of the global burden occurs in Africa, where the disease is endemic, while the Americas experience sporadic outbreaks representing the remaining 8-10%.[135] Recent ecological niche modeling has produced updated global risk maps estimating that 1.54 (95% confidence interval 1.53–1.54) billion people live in areas environmentally suitable for yellow fever transmission, distributed across 54 countries in Africa and South America.[136] The virus is endemic in 34 countries across tropical Africa and 13 countries in South America, encompassing areas with suitable sylvatic and urban transmission cycles supported by vectors such as Aedes and Haemagogus species.[137] Transmission risk zones are confined to these regions, with no sustained human cases reported in Asia despite the presence of competent vectors like Aedes aegypti, likely due to historical absence of viral introduction and potential cross-protective immunity from other endemic flaviviruses.[138] [139] Underreporting complicates precise burden assessment, as factors including limited laboratory confirmation, misdiagnosis with dengue or malaria, and weak health systems in rural areas lead to estimates relying on serological surveys and mathematical models rather than comprehensive case notifications.[140] [141] These models account for asymptomatic infections and mild cases, revealing that official reports capture only a fraction—often less than 10%—of true incidence in high-burden settings.[142]

Endemic Patterns in Africa

Yellow fever maintains endemic transmission across tropical Africa, primarily within latitudes 15°N to 10°S, where the sylvatic cycle predominates, involving non-human primates as reservoirs and forest-dwelling Aedes species such as Aedes africanus as vectors.[76] This zoonotic persistence ensures viral circulation independent of human populations, with spillover to humans occurring through intermediate savannah cycles mediated by Aedes bromeliae or urban cycles via Aedes aegypti, particularly in West and Central Africa.[50] In these regions, ecological proximity between forested wildlife habitats and dense human settlements facilitates frequent human infections, contributing to Africa's disproportionate share of the global burden, estimated at around 200,000 annual cases and 30,000 deaths, largely underreported.[143] Regional variations in incidence reflect ecological differences; West and Central Sub-Saharan Africa bear the highest endemicity due to humid tropical forests supporting robust sylvatic reservoirs and vectors, whereas East Africa experiences lower transmission linked to drier climates and sparser suitable monkey populations and mosquito habitats.[144] For instance, countries like Nigeria, Ghana, and the Democratic Republic of the Congo (DRC) report sustained enzootic activity, with genetic analyses confirming ongoing circulation among non-human primates.[145] Outbreaks in the 2020s, such as the 2021–2022 event in Ghana yielding 70 confirmed cases and a 50% case-fatality rate, and persistent surges in DRC and Angola, underscore vulnerability exacerbated by vaccination coverage below 50% in affected provinces.[146][147] The entrenched sylvatic reservoirs preclude eradication efforts, as vaccination targets only human amplification, leaving wildlife cycles intact and enabling repeated spillovers, in contrast to patterns elsewhere where human-vector disconnection is more feasible.[148] WHO surveillance in 2024 documented probable cases across 13 African countries, including Cameroon and Uganda, highlighting the challenge of controlling a virus sustained by ecologically resilient zoonotic dynamics.[149]

Endemic Patterns in the Americas

In the Americas, yellow fever maintains a predominantly sylvatic transmission cycle confined to forested regions, with the Amazon basin serving as the primary endemic core spanning parts of Brazil, Peru, Bolivia, Colombia, and Guyana.[150] Transmission occurs between non-human primates, such as howler monkeys (Alouatta spp.), and canopy-dwelling mosquitoes of the genera Haemagogus and Sabethes, which are inefficient at sustaining human-to-human spread outside enzootic foci.[151] Hotspots are concentrated in rural Amazonian areas where human encroachment via deforestation and agricultural expansion facilitates spillover from wildlife reservoirs to unvaccinated individuals, often forestry workers or farmers entering endemic zones.[152] Urban cycles, which rely on Aedes aegypti vectors bridging human infections, have been absent in the Americas since the 1940s, with no large-scale outbreaks reported after 1942 despite the vector's presence and occasional imported cases.[153] This interruption stems from early 20th-century vector control efforts and vaccination campaigns that severed domestic chains, contrasting with Africa's mixed urban-sylvatic patterns and highlighting the Americas' reliance on preventing sylvatic spillovers rather than managing established city-based transmission. Epizootics in primates, marked by sudden die-offs, act as natural sentinels for viral circulation, as species like Alouatta exhibit high fatality rates and have been monitored for this purpose since the 1930s.[154] Human cases typically manifest as sporadic spillovers among unvaccinated rural laborers exposed during occupational activities in endemic forests, with infections rarely progressing to sustained community transmission due to the sylvatic vectors' limited adaptation to peridomestic environments.[153] Unlike Africa's enzootic urban potential, the Americas' pattern underscores ecological barriers to amplification, though deforestation-driven habitat fragmentation increases interface risks without evidence of evolutionary shifts toward urban competence. This dynamic parallels the virus's unexplained absence from Asia, where competent vectors like A. aegypti abound but no sustained cycles have established despite historical introductions.[155]

Recent Outbreaks and Trends

In the Americas, yellow fever cases surged in 2025, with 212 confirmed human cases and 85 deaths reported across five countries by late April, yielding a case fatality rate of approximately 40%.[75] This marked a sharp increase from 2024, when 61 cases and 30 deaths were recorded region-wide, primarily in the Amazon basin.[156] By May 2025, cases had extended beyond traditional Amazonian endemic zones into areas like Colombia's Tolima department and parts of Brazil outside forested regions, signaling spillover from sylvatic cycles into human populations.[157] Brazil accounted for the majority, with over 70% of cases linked to unvaccinated individuals in rural and peri-urban interfaces.[152] Contributing factors include persistent vaccination coverage gaps, with suboptimal immunization in at-risk populations allowing sustained sylvatic transmission from non-human primates to humans via Aedes and Haemagogus vectors.[158] Urbanization has facilitated vector adaptation and human encroachment into forested edges, amplifying contact without corresponding boosts in routine vaccination or surveillance.[159] While environmental shifts like deforestation play a role, empirical data from PAHO emphasize immunity deficits and control lapses over climatic variables as primary drivers of the 2025 uptick.[90] In Africa, yellow fever maintains a steady high burden, with an estimated 84,000 to 170,000 severe cases annually across 27 at-risk countries, though no equivalent explosive surge to the Americas' 2025 pattern has been documented in recent reporting.[160] The World Health Organization attributes the continent's ongoing endemicity to similar issues of incomplete vaccination campaigns and urban vector proliferation, yet transmission remains predominantly sylvatic and intermediate rather than urban outbreaks.[2] These trends heighten risks for international travelers to endemic zones, prompting reinforced requirements for vaccination certificates in affected countries and underscoring the need for enhanced cross-border surveillance to preempt imported cases.[156] Observed patterns of geographic expansion suggest potential for recurrent waves absent intensified fractional dosing and routine immunization drives.[161]

Historical Context

Early Epidemics and Recognition

Yellow fever, an acute viral hemorrhagic disease endemic to parts of Africa, was introduced to the Americas during the transatlantic slave trade beginning in the 15th and 16th centuries, as infected individuals and vectors were transported aboard ships from West Africa to the New World.[162] The virus encountered suitable ecological conditions in the Caribbean, including the presence of competent mosquito vectors like Aedes aegypti, which facilitated local transmission cycles.[163] Empirical records from colonial trade logs and ship manifests document recurring outbreaks tied to these maritime routes, with mortality concentrated among non-immune European settlers and indigenous populations lacking prior exposure.[164] The earliest documented epidemics in the Americas occurred in the Caribbean islands during the mid-17th century, with outbreaks reported in Barbados in 1647 and Guadeloupe in 1648, marking the initial establishment of urban transmission in port cities reliant on sugar plantations and slave labor.[165] By the 18th century, the disease had spread northward along trade corridors, affecting continental ports such as Boston in 1693, where victims exhibited jaundice, high fever, and hemorrhagic "black vomit," symptoms chronicled in contemporary physician accounts as distinguishing features of the illness.[166] European observers described these manifestations—icteric skin, conjunctival suffusion, and gastrointestinal bleeding—but attributed them to environmental factors rather than biological agents, reflecting the era's dominant paradigms.[167] A particularly devastating outbreak struck Philadelphia in 1793, originating likely from a ship arriving from the Caribbean, resulting in approximately 5,000 deaths—about 10% of the city's population of roughly 50,000—over August to November, as recorded in municipal burial registries and physician reports like those of Benjamin Rush.[168] [169] These mortality figures, derived from empirical tallies of interments and absenteeism in official ledgers, counter contemporary underestimates that minimized the toll to preserve economic activity, underscoring the disease's lethality among susceptible newcomers.[170] Prevalent explanations invoked the miasma theory, positing that "noxious effluvia" from decaying organic matter in humid ports generated the fever, a view unsubstantiated by causal evidence but reinforced by observational correlations with filth and stagnation until vector transmission was later identified.[171] This misattribution delayed targeted interventions, allowing unchecked propagation via unrecognized mosquito intermediaries.[172]

Scientific Advances in Understanding

In 1881, Cuban epidemiologist Carlos Finlay proposed that yellow fever was transmitted via the bite of the Aedes aegypti mosquito, challenging dominant theories of direct person-to-person contagion or fomite spread.[173] Finlay's hypothesis, presented at the International Sanitary Conference in Washington, D.C., suggested an extrinsic incubation period in the vector but lacked definitive experimental proof at the time, meeting skepticism from contemporaries who favored bacterial or contact-based causation.[174] The breakthrough came in 1900 when the United States Army Yellow Fever Commission, headed by Major Walter Reed, conducted controlled experiments in Cuba using human volunteers. These studies conclusively demonstrated that yellow fever required transmission by the infected Aedes aegypti mosquito, with an extrinsic incubation period of about 12 days, while ruling out fomite or direct contact as vectors through exposure trials yielding no infections.[175][176] Reed's team, including James Carroll, Aristides Agramonte, and Jesse Lazear, exposed volunteers to contaminated bedding and secretions without illness, but mosquito bites from infected sources produced the disease, vindicating Finlay's mosquito-vector theory and shifting paradigms from mythic contagion models to empirical causation.[177] Building on this causal insight, early 20th-century vector control efforts proved effective in urban settings. In Rio de Janeiro, where epidemics had ravaged the city, physician Oswaldo Cruz launched a 1903 campaign as head of the Federal Serum Therapy Institute, systematically eliminating A. aegypti breeding sites through sanitation, larvicide application, and house inspections, eradicating urban transmission by 1907 without reliance on vaccines.[178][179] Further advances clarified the pathogen's nature: in 1927, British pathologist Adrian Stokes isolated the yellow fever virus from the blood of a Ghanaian patient (known as the Asibi strain) by serial passage in rhesus monkeys, confirming its filterable viral etiology—the first human virus isolated—and enabling virological studies that distinguished it from bacterial suspects.[50][180] This isolation overcame prior failures to culture the agent, solidifying understanding of yellow fever as an arboviral disease propagated in sylvatic and urban cycles via mosquito vectors.[181]

Vaccine Era and Control Efforts

The development of the 17D attenuated vaccine strain by Max Theiler in 1937, through serial passage of the Asibi virus in chick embryos, enabled large-scale immunization efforts starting in the late 1930s.[98] This vaccine, administered to millions of Allied troops during World War II, proved highly effective, providing protective immunity in over 95% of recipients for decades or possibly lifelong.[6] Post-war, its deployment alongside urban vector control significantly curtailed yellow fever transmission.[6] In the Americas, mass vaccination campaigns initiated after 1945, combined with aggressive Aedes aegypti eradication programs, eliminated urban yellow fever cycles by interrupting human-mosquito-human transmission.[182] The final confirmed urban outbreak occurred in Brazil in 1942, with no subsequent epidemics reported in the region, averting potential resurgences in densely populated areas despite ongoing sylvatic maintenance in primate reservoirs.[182] [183] However, control limitations persisted due to the infeasibility of eradicating sylvatic vectors in forested habitats, where Haemagogus mosquitoes sustain enzootic cycles among non-human primates, enabling spillover to unvaccinated humans entering endemic zones.[184] In Africa, post-WWII efforts emphasized routine childhood immunization and outbreak responses, achieving partial success in preventing urban epidemics but hampered by vaccine supply shortages, logistical barriers in remote areas, and vaccination coverage often falling below the 80% threshold required for herd immunity.30419X/fulltext) Sylvatic transmission, dominant across much of the continent, resisted full interruption as vector control proved challenging against forest-dwelling mosquitoes, and compliance varied due to factors like population mobility and access issues.[185] [184] The World Health Organization's Eliminate Yellow Fever Epidemics (EYE) strategy, initiated in 2016 as a coalition effort, targeted these gaps by prioritizing preventive mass vaccination campaigns to immunize nearly 1 billion at-risk individuals in Africa by 2026, alongside enhanced surveillance and rapid outbreak containment.[186] [184] While successes included bolstered laboratory diagnostics and higher coverage in select regions, ongoing challenges from sylvatic persistence and supply dependencies highlighted the strategy's reliance on sustained international funding and local adherence to mitigate spillover risks.[187]

Modern Challenges and Resurgences

The 2016 yellow fever outbreak in Angola exemplified vulnerabilities stemming from decades of low population immunity, as the country had not experienced a major epidemic since the 1980s, leaving much of the urban population unvaccinated despite the disease's endemic presence in sylvatic cycles. By July 1, 2016, health authorities reported 3,552 suspected cases across all 18 provinces, including 875 laboratory-confirmed infections and 355 deaths, with rapid urban spread facilitated by Aedes aegypti mosquitoes in densely populated areas. The response was hampered by global vaccine shortages, exhausting emergency stockpiles and necessitating fractional dosing strategies by the World Health Organization, which highlighted systemic underinvestment in production capacity relative to endemic risks.[188][189] In the Americas, a notable uptick in cases during 2025 underscored declines in vaccination coverage following disruptions from the COVID-19 pandemic, with 212 confirmed infections reported through April— a threefold increase over the 61 cases in 2024—primarily among unvaccinated individuals in sylvatic transmission zones of Brazil, Bolivia, Peru, and Colombia. This resurgence, including 74 deaths by early April, reflected coverage drops below herd immunity thresholds (around 80% in endemic areas), exacerbated by logistical challenges in routine immunization programs amid competing public health priorities.[97][190] Globalization amplifies these risks through increased human mobility, enabling spillover from sylvatic to potential urban cycles via international travel, as seen in exported cases from Angola prompting alerts in non-endemic regions like Asia. Ecological shifts, including deforestation and urban expansion favoring Aedes vectors, compound policy gaps, while growing vaccine hesitancy—fueled in part by resistance to mandates and misinformation—erodes uptake in at-risk populations. Critiques of international aid point to inefficiencies, such as over-reliance on reactive emergency stockpiles rather than sustained local production and surveillance, which delayed containment in 2016 despite substantial funding.[153][119][189]

Ongoing Research

Vaccine Innovations

Efforts to develop next-generation yellow fever vaccines address limitations of the live-attenuated 17D strain, including contraindications for immunocompromised individuals, egg-allergic patients, and potential adverse events in older adults, by exploring inactivated and alternative platforms. Inactivated candidates, such as HydroVax-002, utilize hydrogen peroxide inactivation and have advanced to Phase 1 trials evaluating safety and immunogenicity in healthy adults aged 18-49, with doses of 1 mcg and 5 mcg administered in two intramuscular injections.[191] Similarly, XRX-001, another inactivated whole-virus vaccine, entered Phase 1 clinical trials to assess tolerability and antibody responses, prioritizing surrogate endpoints like neutralizing antibodies due to ethical constraints on human challenge studies.[192] These platforms aim to provide safer options for vulnerable populations, with preclinical data demonstrating protective efficacy against lethal challenge in animal models when adjuvanted with alum or CpG.[193][194] Recombinant viral vector and nucleic acid-based candidates offer additional innovation, bypassing live-virus risks while eliciting robust T-cell and antibody responses. The modified vaccinia Ankara-Bavarian Nordic-yellow fever (MVA-BN-YF) vaccine, a non-replicating viral vector expressing yellow fever antigens, completed Phase 1 trials showing comparable immunogenicity to 17D without vaccine-associated viscerotropic disease.[192] DNA vaccine platforms, such as those using immunization DNA (i-DNA) technology, have demonstrated preclinical protection by mimicking live-virus antigen presentation, with potential for rapid manufacturing.[195] Safety profiles in early trials emphasize monitoring for reactogenicity, with efficacy inferred from challenge-protected models in non-human primates, where neutralizing antibody titers correlate with protection.[185] Fractional dosing of the existing 17D vaccine has been validated as an effective strategy to extend supplies during outbreaks, with one-fifth doses achieving seroconversion rates of 97-100% at 28-30 days post-vaccination, non-inferior to full doses in randomized trials during the 2016 Kinshasa outbreak.[196] Long-term follow-up confirms sustained immunogenicity, with 89% of recipients maintaining protective titers at 5 years after fractional 17DD dosing.[197] This approach, endorsed by WHO for emergencies, relies on intradermal administration and has been tested across manufacturers, supporting scalability without compromising safety.[198][199] Production scaling innovations target outbreak responsiveness, with annual global output increasing from 20 million to over 80 million doses since 2001 through expanded facilities and Vero cell-based manufacturing of next-generation candidates like vYF, which matches 17D immunogenicity in Phase 1 while enabling faster surge capacity.[160][200] Germ-free egg technologies and non-egg platforms further mitigate supply chain vulnerabilities, such as avian influenza disruptions, to ensure equitable access amid resurgences driven by urbanization and vaccine hesitancy.[201][185]

Therapeutic Developments

No approved antiviral therapies exist for yellow fever, leaving acute care reliant on supportive measures amid high case-fatality rates of 20-50% in severe infections.[2] Efforts target viral replication directly, as the flavivirus's RNA-dependent RNA polymerase represents a causal vulnerability, though host inflammatory responses also drive pathology. Broad-spectrum inhibitors like galidesivir (BCX4430), an adenosine nucleoside analog, disrupt this polymerase in preclinical models, achieving near-complete protection in yellow fever virus-infected hamsters even when dosing begins four days post-challenge.[202] [203] Galidesivir's hepatic accumulation suits yellow fever's tropism, but human trials remain limited to Phase 1 safety data without yellow fever-specific efficacy endpoints.[204] [205] Monoclonal antibodies derived from human survivors offer another pipeline avenue, neutralizing the virus by binding conserved epitopes on the envelope protein. Eight such antibodies, isolated from convalescent donors, exhibit potent in vitro activity and protect against lethal challenge in animal models when administered prophylactically or therapeutically.[206] Two candidates fully cleared infection markers in preclinical tests, highlighting potential for post-exposure intervention.[80] Recent 2025 data confirm prophylactic and therapeutic efficacy in preventing death, with supersite targeting enhancing breadth against variants.[82] However, scalability and cold-chain requirements pose deployment hurdles in endemic regions. Translation from animal models to humans falters due to incomplete recapitulation of viscerotropic disease; hamsters and mice mimic viremia but not full hepatic necrosis or cytokine storms observed clinically.[55] No standardized non-human primate model fully validates efficacy, complicating licensure pathways.[207] Field trials face ethical barriers, as controlled human challenges are infeasible without vaccination offsets, and outbreak sparsity limits enrollment, underscoring persistent unmet needs for replication-focused interventions over symptomatic palliation.[208] [209]

Epidemiological Modeling

Yellow fever research employs a variety of modeling approaches, encompassing epidemiological dynamical models (e.g., for transmission dynamics and vaccination equilibrium analyses), ecological niche models for predicting global distribution and environmental suitability, and animal models for pathogenesis and vaccine studies. Recent publications highlight the sensitivity of disease burden estimates to modeling assumptions.[136][210] Epidemiological modeling of yellow fever employs compartmental frameworks, such as SEIR (susceptible-exposed-infectious-recovered) extensions like SVEIRS, to simulate transmission dynamics between human hosts and mosquito vectors (Aedes and Haemagogus species). These deterministic models incorporate parameters for incubation periods, vector biting rates, and vaccination efficacy, enabling predictions of outbreak trajectories grounded in vector-virus-host interactions. For instance, stability analyses in SVEIRS models reveal endemic equilibria influenced by reproduction numbers (R_0), typically ranging from 1.5 to 10 depending on environmental conditions, with interventions like vector control reducing R_0 below unity to achieve disease-free states.[211] [212] Advanced iterations integrate spatial factors, including human mobility patterns via network models and climate thresholds like minimum temperatures (around 17–18°C for vector activity), to forecast spillover from sylvatic to urban cycles. Recent multi-disease ecological niche models, incorporating corrections for surveillance biases, have generated updated global risk maps estimating that 1.54 billion people across 54 countries in Africa and South America are at risk of yellow fever. Machine learning enhances risk mapping by analyzing geospatial data—such as vegetation indices, precipitation, and land use—to delineate high-probability transmission zones, outperforming traditional ecological niche models in predictive accuracy for Aedes aegypti-driven outbreaks. These approaches have mapped landscape connectivity for vector dispersal, prioritizing areas with fragmented habitats conducive to mosquito proliferation.[136][213] [214] [215] Validation against empirical data, including the 2025 Americas surge with 212 confirmed cases by late April (a threefold rise from 2024), demonstrates moderate success in projecting case escalation under warming scenarios, where models hindcasted increased suitability in southern Brazil and Colombia. However, discrepancies arise in underreported rural-sylvatic interfaces, where surveillance gaps inflate uncertainty; sensitivity analyses show burden estimates varying up to 50% due to underreporting multipliers and vaccination misclassification. Recent publications continue to highlight the sensitivity of disease burden estimates to modeling assumptions.[97] [213] [216] Such models inform targeted policies, advocating fractional vaccination campaigns in hotspots over blanket coverage to optimize limited doses, as stochastic simulations indicate 70–80% efficacy in curbing urban amplification when focused on high-mobility peri-urban areas. Limitations persist in capturing anthropogenic drivers like deforestation, underscoring the need for hybrid data assimilation from real-time serosurveillance to refine forecasts.[217] [218]

References

  1. Yellow Fever: Causes and How It Spreads - CDC
  2. https://www.who.int/news-room/fact-sheets/detail/yellow-fever
  3. Yellow Fever - StatPearls - NCBI Bookshelf - NIH
  4. Transmission of Yellow Fever Virus - CDC
  5. Yellow Fever: Symptoms, Diagnosis, and Treatment - CDC
  6. The Yellow Fever Vaccine: A History - PMC - NIH
  7. Yellow Fever | Yellow Book - CDC
  8. Biological and Phylogenetic Characteristics of Yellow Fever Virus ...
  9. Genetic Relationships and Evolution of Genotypes of Yellow Fever ...
  10. Biological Characterization of Yellow Fever Viruses Isolated From ...
  11. Phylodynamic Investigation of Yellow Fever Virus Sheds New ...
  12. Phylogenetic and Evolutionary Relationships among Yellow Fever ...
  13. What Does the Future Hold for Yellow Fever Virus? (II) - MDPI
  14. Biological and Phylogenetic Characteristics of Yellow Fever Virus ...
  15. Yellow fever - World Health Organization (WHO)
  16. An Overview of Yellow Fever Virus Disease - PMC - PubMed Central
  17. Yellow Fever: A Reemerging Threat - PMC - PubMed Central - NIH
  18. Mapping environmental suitability of Haemagogus and Sabethes ...
  19. Aedes mosquitoes in the emerging threat of urban yellow fever ...
  20. Yellow Fever | Public Health Ontario
  21. Yellow fever virus: Knowledge gaps impeding the fight against an ...
  22. Aedes aegypti - Factsheet for experts - ECDC
  23. Roads and forest edges facilitate yellow fever virus dispersion
  24. The Impact of Deforestation, Urbanization, and Changing Land Use ...
  25. The role of forest fragmentation in yellow fever virus dispersal
  26. Virus Transmission and Epidemiology - PMC - PubMed Central
  27. Flavivirus Receptors: Diversity, Identity, and Cell Entry - PMC
  28. G Protein-Coupled Receptor Kinase 2 Promotes Flaviviridae Entry ...
  29. Review The interactions of flaviviruses with cellular receptors
  30. What Does the Future Hold for Yellow Fever Virus? (II) - PMC
  31. Yellow fever virus: Genetic and phenotypic diversity and implications ...
  32. [PDF] Yellow Fever
  33. Rewiring cellular networks by members of the Flaviviridae family
  34. The interferon signaling antagonist function of yellow fever virus ...
  35. The Interferon Signaling Antagonist Function of Yellow Fever Virus ...
  36. [PDF] Mechanisms of evasion of the type i interferon antiviral response by ...
  37. Adaptive Diversification Between Yellow Fever Virus West African ...
  38. Genetic Relationships and Evolution of Genotypes of Yellow Fever ...
  39. A single residue in the yellow fever virus envelope protein ... - Nature
  40. Midzonal lesions in yellow fever: A specific pattern of liver injury ...
  41. Revisiting the liver in human yellow fever: Virus-induced apoptosis ...
  42. Microbiology & infectious diseases - Yellow fever - Pathology Outlines
  43. Deficiency of coagulation factors is associated with the bleeding ...
  44. Hypocoagulability in severe yellow fever infection is associated with ...
  45. Yellow fever disease severity and endothelial dysfunction are ...
  46. Yellow fever virus infection triggers proinflammatory and ...
  47. Yellow fever disease severity is driven by an acute cytokine storm ...
  48. Human Genetic Variation and Yellow Fever Mortality during 19th ...
  49. Yellow Fever 2019 Case Definition | CDC
  50. Yellow Fever: Origin, Epidemiology, Preventive Strategies and ...
  51. Clinical Features and Diagnosis of Yellow Fever - CDC
  52. Yellow Fever Clinical Presentation - Medscape Reference
  53. Yellow Fever - Ghana - World Health Organization (WHO)
  54. Understanding yellow fever-associated myocardial injury
  55. Yellow Fever: Roles of Animal Models and Arthropod Vector Studies ...
  56. Analysis of Morbidity and Mortality Due to Yellow Fever in Brazil - PMC
  57. Yellow fever: profile of cases and factors associated with death in a ...
  58. Yellow fever virus is detected in urine and semen almost a month ...
  59. Reporting & Investigation of Yellow Fever | Health & Human Services
  60. Yellow Fever - Infectious Diseases - Merck Manuals
  61. Case definitions for public health surveillance
  62. [PDF] Yellow fever - Epidemic Control Toolkit
  63. Yellow Fever Differential Diagnoses - Medscape Reference
  64. Yellow fever in the diagnostics laboratory - PMC - PubMed Central
  65. Laboratory evaluation of RealStar Yellow Fever Virus RT-PCR kit ...
  66. Laboratory diagnosis of yellow fever virus infection
  67. Yellow Fever Workup - Medscape Reference
  68. Human fatal yellow fever: Immunohistochemical Detection of Viral ...
  69. Ultrasound-guided minimally invasive autopsy as a tool for rapid ...
  70. Treatment and Prevention of Yellow Fever - CDC
  71. Yellow Fever Treatment & Management - Medscape Reference
  72. Yellow Fever | Johns Hopkins Medicine
  73. Yellow Fever Medication: Vaccines, Histamine H2 antagonists ...
  74. Estimating case fatality risk of severe Yellow Fever cases
  75. WHO spotlights deadly yellow fever outbreaks in the Americas
  76. The incidence and mortality of yellow fever in Africa - PubMed Central
  77. Study provides new recommendations on the treatment of ... - ISARIC
  78. Colombian consensus on the care of critically ill patients with ...
  79. Experimental therapies for yellow fever - PMC - PubMed Central
  80. Therapeutic neutralizing monoclonal antibody administration ...
  81. Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human ...
  82. Prophylactic and therapeutic neutralizing monoclonal antibody ...
  83. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
  84. Sofosbuvir inhibits yellow fever virus in vitro and in patients with ...
  85. Sofosbuvir Off-label Treatment of Yellow Fever Patients During an ...
  86. Study Details | NCT03891420 - Clinical Trials
  87. Yellow fever - Immunization, Vaccines and Biologicals
  88. Yellow fever vaccine - PAHO/WHO
  89. Yellow fever mass vaccination campaigns using fractional dose
  90. Yellow Fever - PAHO/WHO | Pan American Health Organization
  91. Yellow fever vaccine support
  92. International Certificate of Vaccination or Prophylaxis (ICVP) - CDC
  93. [PDF] Yellow fever vaccination requirements country list 2020 - WHO PDF
  94. Yellow Fever (YF) vaccination coverage
  95. Yellow fever outbreaks, vaccine shortages and the Hajj and Olympics
  96. A population-level self-controlled case series study | PLOS Medicine
  97. Yellow fever - Region of the Americas
  98. Max Theiler – Facts - NobelPrize.org
  99. Max Theiler – Nobel Lecture - NobelPrize.org
  100. Max Theiler (1899–1972): Creator of the yellow fever vaccine - NIH
  101. The 17D-204 and 17DD yellow fever vaccines - PubMed
  102. Yellow Fever - World Health Organization (WHO)
  103. Yellow Fever Vaccine - CDC
  104. A comprehensive review of yellow fever vaccine breakthrough ...
  105. Grading of Recommendations, Assessment, Development ... - CDC
  106. Yellow Fever Vaccine Information for Healthcare Providers - CDC
  107. Safety - World Health Organization (WHO)
  108. Serious adverse events associated with yellow fever vaccine - PMC
  109. Yellow fever vaccine usage in the United States and risk ... - PubMed
  110. Yellow Fever Vaccine–Associated Viscerotropic Disease ... - CDC
  111. Fatal viscerotropic and neurotropic disease after yellow fever vaccine
  112. Adverse Event Reports Following Yellow Fever Vaccination, 2007-13
  113. Clinical and Immunological Insights on Severe, Adverse Neurotropic ...
  114. Adverse Events Following Yellow Fever Preventive Vaccination ...
  115. Yellow fever vaccine hesitancy and its relationship with contextual ...
  116. Knowledge and Attitudes Regarding the Vaccination of Brazilian ...
  117. Uganda hospitals have hundreds of unused yellow fever jabs due to ...
  118. Yellow fever in southern Colombia: the strategy that dispelled myths ...
  119. https://www.thinkglobalhealth.org/article/why-yellow-fever-demands-a-seat-at-cop30s-climate-negotiations
  120. [PDF] Surveillance and Control of Aedes aegypti andAedes albopictus in ...
  121. Genetic Diversity of Brazilian Aedes aegypti: Patterns following an ...
  122. The first 'mosquito swatter' in the country - IOC/Fiocruz
  123. Worldwide Status of Insecticide Resistance of Aedes aegypti and Ae ...
  124. Pyrethroid resistance in Aedes aegypti - Parasites & Vectors
  125. Insecticide resistance in Aedes aegypti from Tapachula, Mexico
  126. The Effectiveness of Dengue Vector Control: A Meta‐Review
  127. Effectiveness of community participation in vector-borne disease ...
  128. Effectiveness of community participation in vector-borne disease ...
  129. The scientific and technical advisory group on geographical yellow ...
  130. Eliminate yellow fever epidemics (EYE) strategy 2017-2026
  131. ​Lower doses of yellow fever vaccine could be used in emergencies
  132. Fractional-dose yellow fever vaccination: an expert review - PMC
  133. Fractional dose yellow fever vaccination, coming of age - The Lancet
  134. Yellow Fever - WHO | Regional Office for Africa
  135. The Incidence and Trends of Yellow Fever from 1990 to 2021 in ...
  136. The global burden of yellow fever - PMC - PubMed Central - NIH
  137. Countries with risk of yellow fever transmission and countries ...
  138. Yellow fever in Asia–a risk analysis - PMC - PubMed Central
  139. Risk of yellow fever virus transmission in the Asia-Pacific region
  140. Yellow Fever: Epidemiology and Prevention - Oxford Academic
  141. Burden is in the eye of the beholder: Sensitivity of yellow fever ...
  142. Yellow fever factsheet
  143. The global burden of yellow fever - eLife
  144. The incidence and mortality of yellow fever in Africa: a systematic ...
  145. Persistent Yellow Fever Virus Circulation among Non-Human ...
  146. Molecular Characterization of Circulating Yellow Fever Viruses from ...
  147. Exploring the national burden and challenges in the fight... - LWW
  148. A proposed One Health approach to control yellow fever outbreaks ...
  149. Yellow fever – African Region (AFRO)
  150. Yellow fever outbreaks in South America: Current epidemiology ...
  151. Yellow Fever Virus in Mosquitoes from Rainforest Bordering Manaus ...
  152. Yellow Fever 'Spillover' From Animals In Amazon Basin Is Fueling ...
  153. Yellow fever's distressing return: a wake-up call for public health in ...
  154. Outbreak of Yellow Fever among Nonhuman Primates, Espirito ...
  155. The Absence of Yellow Fever in Asia: History, Hypotheses, Vector ...
  156. Public health risk of yellow fever remains high in the Americas due ...
  157. [PDF] Epidemiological Alert Yellow fever in the Americas Region - PAHO
  158. Re-emergence of yellow fever in the neotropics — quo vadis?
  159. Yellow fever in South America in 2025: a concerning increase, but a ...
  160. Yellow fever resurgence: An avoidable crisis? | npj Vaccines - Nature
  161. Yellow fever in Africa and the Americas - PubMed Central - NIH
  162. Yellow Fever | Viruses, Plagues, and History - Oxford Academic
  163. The First Yellow Fever Pandemic: Slavery and Its Consequences
  164. The Viral Most Wanted: The Flavivirus Family - CEPI
  165. Historical Guide to Yellow Fever | American Experience - PBS
  166. History of Yellow Fever in the U.S. - American Society for Microbiology
  167. Yellow Fever - Encyclopedia of Greater Philadelphia
  168. Major American Epidemics of Yellow Fever (1793-1905) - PBS
  169. The Yellow Fever Epidemic in Philadelphia, 1793 | Contagion
  170. Yellow fever epidemics and mortality in the United States, 1693–1905
  171. Yellow Fever Timeline: The History Of A Long Misunderstood Disease
  172. Carlos Finlay and Yellow Fever: Triumph over Adversity
  173. Carlos Finlay (1833-1915) | American Experience - PBS
  174. Walter Reed and the Scourge of Yellow Fever - UVA Today
  175. [Centenary of the discovery of yellow fever virus and its transmission ...
  176. Walter Reed and the Yellow Fever Experiments - Oxford Academic
  177. Combating Yellow Fever - Biblioteca Virtual Oswaldo Cruz
  178. Oswaldo Cruz - Linda Hall Library
  179. Yellow Fever: 100 Years of Discovery | Global Health - JAMA Network
  180. Yellow Fever: A Brief History of a Tropical Virosis - PubMed
  181. Yellow fever, the returning epidemic - PAHO/WHO
  182. Yellow Fever: A Perennial Threat - ScienceDirect.com
  183. [PDF] Global Strategy to Eliminate Yellow fever Epidemics (EYE)
  184. Re-thinking yellow fever vaccines: fighting old foes with new ...
  185. Nearly one billion people in Africa to be protected against yellow ...
  186. Yellow fever resurgence: An avoidable crisis? - PubMed Central
  187. Resurgence of Yellow Fever in Angola, 2015–2016 - PMC - NIH
  188. Yellow Fever in Angola and Beyond — The Problem of Vaccine ...
  189. Recent outbreaks in the Americas underscore need to urgently ...
  190. Trial of an Inactivated Yellow Fever Virus Vaccine
  191. Immunogenicity and protective activity of mRNA vaccine candidates ...
  192. Development of a hydrogen peroxide-inactivated vaccine that ...
  193. Enhancing Inactivated Yellow Fever 17D Vaccine-Induced Immune ...
  194. Re-thinking yellow fever vaccines: fighting old foes with new ...
  195. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever ...
  196. Immunological response to fractional-dose yellow fever vaccine ...
  197. Immunogenicity and safety of fractional doses of yellow fever vaccines
  198. Yellow Fever Vaccine Dose: How Low Can You Go?
  199. Safety and immunogenicity of a next-generation live-attenuated ...
  200. Germ-free egg-based vaccines for yellow fever - Labiotech.eu
  201. BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow ...
  202. BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against ...
  203. An update on the progress of galidesivir (BCX4430), a broad ...
  204. BioCryst Completes Phase 1 Clinical Trial of Galidesivir
  205. A neutralizing-protective supersite of human monoclonal antibodies ...
  206. The Present and Future of Yellow Fever Vaccines - MDPI
  207. Controlled Human Infection Models To Accelerate Vaccine ...
  208. Dengue and Yellow Fever — Challenges for the Development and ...
  209. Modelling and stability analysis of SVEIRS yellow fever two host model
  210. Epidemiological Modelling of Yellow Fever Dynamics - ResearchGate
  211. Risk assessment and mitigation evaluation of future yellow fever ...
  212. Exploring Machine Learning to Map Yellow Fever Risk - Unicef
  213. A machine-learning approach to track how yellow fever mosquito ...
  214. Burden is in the eye of the beholder: Sensitivity of yellow fever ...
  215. Risk assessment and mitigation evaluation of future yellow fever ...
  216. [PDF] Sensitivity of yellow fever disease burden estimates to modeling ...
  217. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever
  218. Yellow Fever: Roles of Animal Models and Arthropod Vector Studies in Understanding Epidemic Emergence
  219. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever
  220. Yellow fever - Fact sheet
User Avatar
No comments yet.